1 **Viral mimicry of p65/RelA transactivation domain to inhibit NF-κB activation**

2

3 Jonas D. Albarnaz^{1*}, Hongwei Ren^{1†}, Alice A. Torres¹, Evgeniya V. Shmeleva^{1‡}, Carlos A.
4 Melo², Andrew J. Bannister², Geoffrey L. Smith^{1*}

5 ¹Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK

6 ²The Gurdon Institute, University of Cambridge, Cambridge CB2 1QN, UK

7

8 *Corresponding authors: gls37@cam.ac.uk (GLS); jd732@cam.ac.uk (JDA)

9

10 [†]Present address: Department of Immunology and Inflammation, Imperial College
11 London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK

12 [‡]Present address: Department of Obstetrics and Gynaecology, University of Cambridge, Box
13 223, Level 2, The Rosie Hospital, Robinson Way, Cambridge CB2 2SW, UK

14

15 Running title: Viral inhibition of NF-κB via molecular mimicry

16

17 Key words: vaccinia virus, NF-κB, molecular mimicry, p65, CBP, BRD4, virulence, immune
18 evasion, poxvirus

1 ABSTRACT

2 The evolutionary arms race between hosts and their viruses drove the evolution of complex
3 immune systems in mammals and sophisticated immune evasion mechanisms by viruses.
4 Mammalian antiviral defences require sensing of virus infection and stimulation of the
5 expression of interferons and cytokines via the activation of NF- κ B and other immune
6 signalling pathways. Viruses antagonise these host antiviral defences by interfering with
7 immune sensing and signal transduction and blocking the actions of interferons and
8 cytokines. Here we show that a viral protein mimics the transcription activation domain of
9 p65, the transcriptionally active subunit of NF- κ B. The C terminus of vaccinia virus (VACV)
10 protein F14 (residues 51-73) activates transcription when fused to a DNA-binding domain-
11 containing protein and associates with NF- κ B co-activator CBP, disrupting its interaction with
12 p65. Consequently, F14 diminishes CBP-mediated acetylation of p65 and the downstream
13 recruitment of RNA polymerase II processivity factor BRD4 to the promoter of NF- κ B-
14 responsive gene *CXCL10*, thereby inhibiting the expression and secretion of CXCL10 upon
15 stimulation with TNF- α . A VACV strain engineered to lack F14 caused reduced lesions in an
16 intradermal model of infection, showing that F14 contributes to virulence. Our results
17 uncover a mechanism by which viruses disarm the antiviral defences through molecular
18 mimicry of a conserved protein of the host's immune system.

19

1 INTRODUCTION

2 Viruses provide constant selective pressure shaping the evolution of the immune systems of
3 multicellular organisms [1-3]. At the cellular level, an array of receptors detect virus-derived
4 molecules, or more broadly pathogen-associated molecular patterns (PAMPs), allowing the
5 recognition of invading viruses and the activation of a gene expression programme that
6 initiates the antiviral response [reviewed by [4, 5]]. The induced gene products, which
7 include interferons, cytokines and chemokines, are secreted and function as signals to
8 activate more specialised immune cells and attract them to the site of infection, thereby
9 generating inflammation [reviewed by [6-8]]. This coordinated inflammatory response
10 evolved to achieve the control and (or) elimination of the infection, and the establishment of
11 an immunological memory against future infection [reviewed by [4, 9]].

12 Engagement of pattern recognition receptors (PRRs) by their cognate PAMPs activates
13 multiple transcription factors, including nuclear factor kappa light-chain enhancer of activated
14 B cells (NF- κ B) [reviewed by [10-12]]. NF- κ B is a homo- or heterodimer of Rel proteins, with
15 the heterodimer of p50 (also known as NF- κ B1 or NFKB1) and p65 (also known as RelA or
16 RELA) being the prototypical form of NF- κ B [13]. Through an interface formed by the Rel
17 homology domains of the two Rel subunits, NF- κ B recognises and binds to a consensus
18 DNA sequence in the promoter elements and enhancers of target genes [reviewed by [10],
19 [14]]. NF- κ B-responsive gene products include inflammatory mediators, such as cytokines,
20 chemokines and cell adhesion molecules, as well as proteins involved in other immune
21 processes, like MHC molecules, growth factors and regulators of apoptosis [15, 16].
22 Moreover, cytokines, such as interleukin (IL)-1 and tumour necrosis factor (TNF)- α , also
23 trigger NF- κ B activation upon engagement of their receptors on the cell surface [reviewed by
24 [10, 11]].

25 In resting conditions, NF- κ B remains latent in the cytoplasm bound to the inhibitor of κ B
26 (I κ B) α (also known as NFKBIA) [17, 18]. Upon activation, the I κ B kinase (IKK) complex
27 phosphorylates I κ B α , triggering its ubiquitylation and subsequent proteasomal degradation,
28 thus releasing NF- κ B to accumulate in the nucleus [18] [reviewed by [10, 11]]. In the
29 nucleus, NF- κ B interacts with chromatin remodelling factors, coactivators and general
30 transcription factors to activate the transcription of antiviral and inflammatory genes by RNA
31 polymerase (RNAP) II [14, 19-24]. The specificity and kinetics of NF- κ B-dependent gene
32 expression is determined by several factors including dimer composition [25], cooperation
33 with other transcription factors [the cooperation between NF- κ B, activator protein (AP)-1 and
34 interferon regulatory factor (IRF) transcription factors to activate interferon (IFN)- β
35 transcription in response to virus infection being a classical example [26]], duration of the
36 stimulus [27, 28], cell type [29, 30] and chromatin context on the promoters of target genes
37 [14, 31, 32]. In addition, NF- κ B undergoes multiple posttranslational modifications, in the
38 cytoplasm or nucleus, that control its transcriptional activity through interactions with
39 coactivators and basal transcription machinery [reviewed by [13, 33, 34]].

40 Following the stimulation with PAMPs (e.g. lipopolysaccharide) or inflammatory cytokines
41 (e.g. TNF- α), two conserved residues in p65 are phosphorylated: Ser²⁷⁶, mainly by protein
42 kinase A (PKA), and Ser⁵³⁶ within the transactivation domain (TAD), by the IKK complex [35,
43 36]. Phosphorylation of either site enhances NF- κ B transcriptional activity by promoting the
44 interaction with the coactivators CREB-binding protein (CBP) or its paralogue p300 (also
45 known as CREBBP and EP300, respectively). These coactivators acetylate p65 at Lys³¹⁰ as
46 well as histones on the target gene promoters to allow transcription initiation and elongation
47 to proceed [36-39]. The bromodomain and extraterminal domain (BET) protein BRD4 docks

onto acetylated p65 Lys³¹⁰ via its two bromodomains and subsequently recruits positive transcription elongation factor b (P-TEFb) to drive transcription of inflammatory genes by RNAP II [40]. This latter study highlighted the complexity of the gene expression programme downstream of NF- κ B, with subsets of genes differentially expressed depending on the transcriptional regulatory events following NF- κ B recruitment to DNA [[40-42]; reviewed by [43]].

The confrontations between viruses and hosts leave genetic signatures over their evolutionary histories [3, 44]. On one hand, host innate immune factors display strong signs of positive selection to adapt to the pressure posed by viruses [reviewed by [45]]. On the other hand, viruses acquire multiple mechanisms to antagonise host innate immunity, such as mimicking host factors to disrupt their functions in the antiviral response or to subvert them for immune evasion [reviewed by [45, 46]]. Poxviruses have been a paradigm in the study of virus-host interactions [reviewed by [47]]. Their large DNA genomes encode a plethora of proteins that antagonise the host antiviral response. Some poxvirus proteins show structural similarity to host proteins and modulate innate immune signalling during infection [reviewed by [48, 49]].

Vaccinia virus (VACV), the smallpox vaccine and the prototypical poxvirus, utilises molecular mimicry to antagonise the host response to infection [reviewed by [50]]. VACV-encoded soluble receptors of TNF and IL-1 β share amino acid similarity with their cellular counterparts and bind to extracellular cytokines to block the engagement of the cognate cellular receptors and thereby the activation of downstream signalling pathways, including NF- κ B [reviewed by [50, 51]]. VACV also encodes a family of proteins sharing structural similarity to cellular Bcl-2 proteins despite very limited sequence similarity. Viral Bcl-2-like proteins have evolved to perform a wide range of functions, such as inhibition of NF- κ B activation [reviewed by [52]]. One example is VACV protein A49, which notwithstanding its Bcl-2 fold, also mimics the I κ B α phosphodegron that is recognised by the E3 ubiquitin ligase β -TrCP, thereby blocking I κ B α ubiquitylation [53, 54]. Upon NF- κ B activation, the IKK complex phosphorylates A49 to create the complete phosphodegron mimic that then engages with β -TrCP to prevent I κ B α ubiquitylation [55].

Previous work from our laboratory predicted that VACV encodes additional inhibitors of NF- κ B because a mutant VACV strain (vv811 Δ A49) lacking the function of all known inhibitors of NF- κ B still suppresses NF- κ B-dependent gene expression without preventing NF- κ B translocation to the nucleus [56]. Here, we mapped this NF- κ B inhibitory activity to the open reading frame (ORF) *F14L*, which is conserved across all orthopoxviruses including the human pathogens variola, monkeypox and cowpox viruses. Using a combination of gene expression and protein-based assays, we show that F14 from VACV inhibits NF- κ B when expressed ectopically or during infection. Furthermore, a VACV strain lacking F14 has reduced virulence in a mouse model. Mechanistically, the F14 C terminus mimics the transactivation domain (TAD) of p65 and outcompetes p65 for binding to the coactivator CBP. As a consequence, F14 reduces p65 acetylation and downstream molecular events required for the activation of a subset of NF- κ B-responsive inflammatory genes.

1 RESULTS

2 *Vaccinia virus protein F14 is a virulence factor that inhibits NF-κB activation*

3 The prediction that VACV encodes additional inhibitor(s) of NF-κB that function downstream
4 of p65 translocation into the nucleus [56], prompted a search for nuclear NF-κB inhibitors.
5 VACV strain vv811ΔA49 lacks 56 ORFs, but retains the inhibitor(s) [56, 57], and so its
6 encoded proteins were screened by bioinformatics for ones that met the following criteria: (i)
7 early expression, based on previous VACV transcriptome studies [58, 59]; (ii) predicted not
8 to be involved in replication and/or morphogenesis; (iii) being poorly characterised; (iv)
9 presence of putative nuclear localisation signals (NLS) or predicted molecular mass <40 kDa
10 that would allow diffusion into the nucleus [60]; and (v) the presence of domains indicative of
11 function. The genomic position of the ORF and its conservation among orthopoxviruses were
12 also considered given that VACV immunomodulatory genes are located towards the genome
13 termini and are sometimes less conserved than genes centrally located that have functions
14 in virus replication [61].

15 This approach yielded a list of seven ORFs, namely *F6L*, *F7L*, *F14L*, *A47L*, *B6R*, *B11R* and
16 *B12R*. These ORFs were codon-optimised for expression in human cells, cloned into
17 pcDNA4/TO and tested for inhibition of NF-κB activation in an NF-κB luciferase reporter
18 gene assay. Protein F14 inhibited TNF-α and IL-1β-stimulated NF-κB activity in HEK 293T
19 cells in a dose-dependent manner (Figure 1A, B and Figure S1). This inhibitory activity was
20 specific for the NF-κB pathway, because F14 did not affect IFN-α-stimulated Janus kinase
21 (JAK)/signal transducer and activators of transcription (STAT) or phorbol 12-myristate 13-
22 acetate (PMA)-stimulated mitogen-activated protein kinase (MAPK)/AP-1 pathways (Figure
23 1C, D). The inhibitory activity was exerted despite the lower levels of F14 expression when
24 compared to VACV protein B14, a known inhibitor of NF-κB (Figure 1E) [62]. Conversely,
25 VACV protein C6 suppressed type I IFN signalling and B14 upregulated AP-1 activity, as
26 observed previously (Figure 1C, D) [63, 64].

27 Most VACV immunomodulatory proteins affect virulence in intranasal or intradermal murine
28 models [reviewed by [50, 51]]. To evaluate if loss of F14 expression affected virulence, a
29 recombinant VACV lacking F14 was generated, termed vΔF14. Intradermal inoculation of the
30 ear pinnae of mice with vΔF14 produced smaller lesions, and reduced virus titres at 7 and 10
31 d post-infection (p.i.) (Figure 1F, G) compared to wild type virus (vF14) and a revertant strain
32 (vF14-Rev), generated by reinserting F14 into vΔF14 at its natural locus (Figure 1F).
33 Attenuation of vΔF14 in the intradermal mouse model correlated with reduced viral titres in
34 the infected ears 7 and 10 d p.i., but not 3 d p.i. (Figure 1G). In contrast, in an intranasal
35 mouse model vΔF14 caused the same extent of body mass loss as wild type and revertant
36 controls (Figure S2). In cell culture, vF14, vΔF14 and vF14-Rev displayed no differences in
37 replication and plaque size (Figure S3). Altogether, these experiments showed that F14 is
38 not essential for virus replication but makes a modest contribution to virulence.

39 Previous analyses of VACV transcriptome showed that the *F14L* ORF is transcribed and
40 translated early during infection [58, 59, 65]. This was consistent with an upstream typical
41 early promoter and a transcription termination motif T₅NT downstream of the stop codon [66,
42 67]. To investigate F14 expression during infection, a VACV strain was constructed in which
43 F14 was tagged with a C-terminal TAP tag. The vF14-TAP strain replicated normally (Figure
44 S3) and immunoblotting showed F14 expression from 4 h p.i. and peaked by 8 h p.i.,
45 matching the accumulation of another early VACV protein C6 (Figure 1H) [68]. F14 levels
46 were notably lower compared to other VACV proteins tested either when expressed
47 ectopically (Figure 1E) or during infection (Figure 1H). This might explain why F14 was not

detected in our recent quantitative proteomic analysis of VACV infection, which detected about 80% of the predicted VACV proteins [69]. Pharmacological inhibition of virus DNA replication with cytosine arabinoside (AraC) did not affect F14 protein levels, consistent with early expression, whereas late protein D8 was inhibited (Figure 1H).

The existence of multiple VACV inhibitors of NF- κ B that each contribute to virulence indicates they are not redundant. To test if F14 affects NF- κ B activation in cell culture we deleted F14 from the vv811 Δ A49 strain that lacks other known inhibitors of NF- κ B [56] and infected an NF- κ B firefly luciferase reporter A549 cell line [56]. As shown previously, vv811 Δ A49 inhibited NF- κ B to a reduced extent when compared to the parental vv811 strain (Figure 1I) [56] and deletion of *F14L* reduced NF- κ B inhibition further (Figure 1I). Immunoblotting confirmed equal infection with these viruses (Figure 1J). Notably, vv811 Δ A49 Δ F14 still suppressed NF- κ B activation considerably, which might be explained by: (i) the existence of additional virally-encoded inhibitors that cooperate to inhibit NF- κ B in the nucleus, or (ii) the actions of D9 and D10 decapping enzymes to reduce host mRNA [70, 71].

F14 inhibits NF- κ B at or downstream of p65

To dissect how F14 functions, its impact on three hallmarks of NF- κ B signalling were studied: namely degradation of I κ B α , phosphorylation of p65 at S536 and p65 nuclear translocation. A HEK 293T-derived cell line that expresses F14 inducibly upon addition of doxycycline, was used to study the degradation of I κ B α , and phosphorylation and nuclear translocation of p65 following stimulation with TNF- α . I κ B α degradation was evident 15 min after stimulation and its re-synthesis had started by 30 min, but neither process was influenced by F14 (Figure 2A). F14 also did not affect phosphorylation of p65 at Ser⁵³⁶ (Figure 2A) or p65 translocation into the nucleus as measured by immunofluorescence (Figure 2B). In contrast, VACV protein B14 inhibited translocation efficiently as reported [62], and VACV protein C6, an IFN antagonist [63, 68], did not (Figure 2B).

Next, the NF- κ B inhibitory activity of F14 was tested by reporter gene assay following pathway activation by p65 overexpression. In contrast to B14, F14 inhibited p65-mediated activation in a dose-dependent manner without affecting p65 levels (Figure 2C). Altogether, these results showed that F14 blocks NF- κ B in the nucleus at or downstream of p65. F14 thus fits the criteria described previously for the unknown inhibitor of NF- κ B encoded by VACV and expressed by vv811 Δ A49 [56].

F14 orthologues are conserved in orthopoxviruses and mimic the p65 transactivation domain

Poxvirus immunomodulatory proteins are generally encoded in the variable genome termini, rather than the central part of the genome that encodes proteins for virus replication, share lower sequence identity and show genus-specific distribution [61]. Even among orthopoxviruses, only a few of the immunomodulatory genes are present in all virus species [61]. Nonetheless, Viral Orthologous Clusters [72] and protein BLAST searches found orthologues of VACV F14 in all orthopoxviruses, with 70.7% to 98.6% amino acid (aa) identity (Figure 3A). The C-terminal half of F14 was more conserved and included a predicted coiled-coil region (aa 34-47), the only structural motif predicted via bioinformatic analyses. However, the Phyre2 algorithm [73] predicted the C-terminal aa 55 to 71 to adopt an α -helical secondary structure similar to that of aa 534-546 of p65 in complex with the PH

domain of human general transcription factor Tfb1, or aa 534-550 of p65 in complex with the KIX domain of NF- κ B coactivator CBP [74]. The F14 aa similarity was striking, particularly with p65 aa within a ϕ xx ϕ motif essential for NF- κ B transcription activity [74, 75]. The C terminus of p65 harbours its transactivation domain (TAD), which is divided into two subdomains that are transcriptionally independent: TA₁ (aa 521 to 551) and TA₂ (aa 428 to 521) [22, 76]. TA₁ contributes at least 85% of p65 transcriptional activity and interacts directly with CBP [22, 74, 76]. Notably, in F14 the position equivalent to Ser⁵³⁶ in p65, which is phosphorylated upon NF- κ B activation [35, 39], is occupied by the negatively charged residue Asp⁵⁹, a phospho-mimetic (Figure 3A).

These observations and the key role of CBP in NF- κ B-dependent gene activation [20], prompted the investigation of whether F14 could interact with CBP. Immunoprecipitation (IP) of HA-tagged F14 co-precipitated CBP-FLAG from HEK 293T cells (Figure 3B). Reciprocal IP experiments showed that ectopic CBP co-precipitated F14-HA, but not GFP-HA, with or without prior TNF- α stimulation (Figure 3C). These interactions were also seen at endogenous levels in both HEK 293T and HeLa cells infected with vF14-TAP. F14, but not C6, co-precipitated endogenous CBP (Figure 3D).

To test whether the C terminus of F14 mediated transactivation via its binding to CBP, F14 aa 51 to 73 were fused to the C terminus of a p65 mutant lacking the TA₁ subdomain of the TAD (Δ TA₁) and the fusion protein was tested in a NF- κ B luciferase reporter gene assay. Compared to wildtype p65, the p65 Δ TA₁ mutant was impaired in its transactivating activity, which was restored to wildtype levels upon fusion to F14₅₁₋₇₃ (Figure 3E). This result argues strongly that the C terminus of F14 mimics the TA₁ of p65 and this mimicry might explain how F14 inhibits NF- κ B activation.

F14 outcompetes NF- κ B for binding to CBP

The similarity between the C termini of F14 and p65 led us to investigate if the conserved aa contributed to the NF- κ B inhibitory activity of F14. Based on the structure of CBP KIX domain in complex with p65 TA₁ [74], residues of F14 TAD-like domain corresponding to residues of p65 important for its binding to CBP were mutated. Three sites were altered by site-directed mutagenesis of F14: the dipeptide Asp^{62/63}, and the following Leu⁶⁵ and Leu⁶⁸ of the ϕ xx ϕ motif. F14 L65A or L68A still inhibited NF- κ B efficiently (Figure 4A). In contrast, mutation of Asp^{62/63} to either alanine (D62/63A) or lysine (D62/63K) abolished the inhibitory activity (Figure 4A). Protein expression was comparable across the different F14 mutants (Figure 4A). The loss of NF- κ B inhibitory activity of D62/63A and D62/63K mutants correlated with their reduced capacity to co-precipitate CBP, whereas L65A and L68A mutants co-precipitated CBP to the same extent as wildtype F14 (Figure 4B). The mutation of the negatively charged Asp^{62/63} to positively charged Lys residues was more efficient in disrupting the interaction between F14 and CBP than only abolishing the charge (Figure 4B). Collectively, these results highlight the importance of the negatively charged dipeptide Asp^{62/63} within the TAD-like domain for NF- κ B inhibition by F14.

Next we tested if F14 could disrupt the interaction of p65 with its coactivator CBP [20]. HEK 293T cells were transfected with vectors expressing p65 and CBP or RIG-I, and VACV proteins F14 or C6. The amount of p65-HA immunoprecipitated by ectopic CBP was reduced by increasing amounts of F14 but not C6 (Figure 5A, B). Quantitative analysis showed equivalent ectopic CBP immunoprecipitation with or without F14 (Figure 5C). Furthermore, the mutation D62/63K diminished the capacity of F14 to disrupt the interaction of CBP and

p65 (Figure 5D). This observation correlated well with the reduced capacity of the D62/63K mutant to co-precipitate CBP (Figure 4B).

F14 suppresses expression of a subset of NF-κB-responsive genes

To address the impact of F14 on the induction of endogenous NF-κB-responsive genes by TNF-α, the T-REx-293 cell lines inducibly expressing F14 or C6 were utilised (Figure 6G). NF-κB-responsive genes display different temporal kinetics upon activation, with “early” gene transcripts peaking between 30 – 60 min after stimulation before declining, whilst “late” gene transcripts accumulate slowly and progressively, peaking 3 h post stimulation [15, 16]. In F14-expressing cells, mRNAs of *NFKBIA* and *CXCL8* “early” genes had equivalent induction kinetics compared to C6-expressing cells (Figure 6A, B). The lack of inhibition of F14 on the expression of *NFKBIA* mRNA is in agreement with the previous finding that the re-synthesis of IκBα (*NFKBIA* protein product) is unaffected by F14 after its proteasomal degradation induced by TNF-α (Figure 2A). Conversely, F14 inhibited the accumulation of the mRNAs of *CCL2* and *CXCL10* “late” genes in response to TNF-α (Figure 6D, E).

CXCL8 and *CXCL10* encode chemokines CXCL8 and CXCL10 (also known as IL-8 and IP-10, respectively) that are secreted from stimulated cells. Following induction of VACV protein expression (Figure 6H) the levels of these chemokines were measured by ELISA and showed that secretion of CXCL10, but not CXCL8, was inhibited by F14. In contrast, the secretion of both chemokines was inhibited, or unaffected, by VACV proteins B14 or C6, respectively, as expected (Figure 6C, F). An inhibitor of IKKβ, B14 inhibited the secretion of chemokines, whereas C6, an inhibitor of IRF3 and type I IFN signalling, had a negligible effect (Figure 6C, F). Thus, unlike other VACV NF-κB inhibitors, F14 inhibits only a subset of NF-κB-responsive genes.

Acetylation of p65 and recruitment of BRD4 are inhibited by F14

Posttranslational modifications of p65 accompany NF-κB translocation to the nucleus and some, such as acetylation by acetyltransferases CBP and p300, are associated with increased transcriptional activity [136, 137, 139]; reviewed by [13, 33, 34]. F14 did not interfere with the phosphorylation of p65 at Ser⁵³⁶ (Figure 2A), and so the acetylation of p65 Lys³¹⁰, was investigated. T-REx-293 cell lines that inducibly express F14 or contain the empty vector (EV) control were transfected with plasmids expressing p65 and CBP in the presence of the inducer, doxycycline. Although both cell lines expressed equivalent amounts of ectopic p65 and CBP, the amount of p65 acetylated at Lys³¹⁰ was greatly diminished by F14 (Figure 7A). Quantitative analysis showed acetylated p65 was reduced 90% by F14 (Figure 7B). This result, together with the results presented in Figure 5, indicated that the reduced acetylation of p65 was due to disruption of the interaction between p65 and CBP by F14.

BRD4 docks onto acetylated histones and non-histone proteins and recruits transcriptional regulatory complexes to the chromatin [reviewed by [77]]. For instance, acetylated Lys³¹⁰ on p65 serves as a docking site for the bromodomains 1 and 2 of BRD4, which then recruits P-TEFb to promote RNAP II elongation during transcription of some NF-κB-responsive genes [40]. The differential sensitivity of TNF-α-stimulated genes to the inhibition of NF-κB by F14 might reflect the differential requirement of p65 acetylated at Lys³¹⁰, and the subsequent recruitment of BRD4, to activate the expression from NF-κB-responsive promoters [40]. This hypothesis was tested by chromatin immunoprecipitation with an anti-BRD4 antibody

followed by quantitative PCR of the promoters of two representative genes: *NFKBIA*, insensitive to F14 inhibition, and *CXCL10*, sensitive to inhibition. BRD4 was recruited to both promoters after TNF- α stimulation, with BRD4 present on *NFKBIA* promoter at 1 and 5 h post-stimulation, whereas BRD4 was evident on *CXCL10* promoter only at 5 h post-stimulation, mirroring the kinetics of mRNA accumulation (Figure 7C; see Figure 6E). In the presence of F14, the recruitment of BRD4 to *NFKBIA* promoter remained unaffected, whilst its recruitment to *CXCL10* was blocked (Figure 7C). This strongly suggests that inhibition of acetylation of p65 at Lys³¹⁰ by F14 is relayed downstream to the recruitment of BRD4 to the “F14-sensitive” *CXCL10* promoter, but not to the “F14-insensitive” *NFKBIA* promoter.

F14 is a unique viral antagonist of NF- κ B

The TAD domain of p65 belongs to the class of acidic activation domains, characterised by a preponderance of Asp or Glu residues surrounding hydrophobic motifs [22]. VP16 is a transcriptional activator from herpes simplex virus (HSV) type 1 that bears a prototypical acidic TAD (Figure 8A) and inhibits the expression of virus-induced IFN- β by association with p65 and IRF3 [78]. Although the VP16-mediated inhibition of the IFN- β promoter was independent of its TAD, we revisited this observation to investigate the effect of VP16 more specifically on NF- κ B-dependent gene activation. VP16 inhibited NF- κ B reporter gene expression in a dose-dependent manner and deletion of the TAD reduced NF- κ B inhibitory activity of VP16 about 2-fold, but some activity remained (Figure 8A).

A search for other viral proteins that contain motifs resembling the $\phi x x \phi \phi$ motif present in acidic transactivation domains detected a divergent $\phi x x \phi \phi$ motif in the protein E7 (aa 79-83) from the high-risk human papillomavirus (HPV) 16, with acidic residues upstream (Asp⁷⁵) or within (Glu⁸⁰ and Asp⁸¹) the motif (Figure 8B). E7 has been reported to inhibit NF- κ B activation, in addition to its role in promoting cell cycle progression [79-82]. We confirmed that HPV-16 protein E7 inhibits NF- κ B-dependent gene expression, albeit to a lesser extent than VACV F14 or HSV-1 VP16 (Figure 8B). Furthermore, E7 mutants harbouring aa substitutions that inverted the charge of Asp⁷⁵ (D75K) or added a positive charge to the otherwise hydrophobic Leu⁸³ (L83R) were impaired in their capacity to inhibit NF- κ B (Figure 8B).

Lastly, the ability of VP16 and E7 to associate with CBP was assessed after ectopic expression in HEK 293T cells. Neither VP16 nor E7, like VACV protein C6 used as negative control, co-precipitated CBP under conditions in which F14 did (Figure 8C). These findings indicate that the mimicry of p65 TAD by F14 is a strategy unique among human pathogenic viruses to suppress the activation of NF- κ B.

DISCUSSION

The inducible transcription of NF- κ B-dependent genes is a critical response to virus infection. After binding to κ B sites in the genome, NF- κ B promotes the recruitment of chromatin remodelling factors, histone-modifying enzymes, and components of the transcription machinery to couple the sensing of viral and inflammatory signals to the selective activation of the target genes. In response, viruses have evolved multiple evasion strategies, including interference with NF- κ B activation. VACV is a paradigm in viral evasion mechanisms, inasmuch as this poxvirus encodes 15 proteins known to intercept the signalling cascades downstream of PRRs and cytokine receptors that activate NF- κ B [reviewed by [50, 51], [83, 84]]. Nonetheless, a VACV strain lacking all these inhibitors still prevented NF- κ B activation after p65 translocation into the nucleus [56] indicating the existence of other inhibitor(s).

Here VACV protein F14 is shown to inhibit NF- κ B activation within the nucleus and its mechanism of action is elucidated. First, ectopic expression of F14 reduces NF- κ B-dependent gene expression stimulated by TNF- α or IL-1 β (Figure 1A, B). Second, F14 is expressed early during VACV infection, and is small enough (8 kDa) to diffuse passively into the nucleus after expression in cytoplasmic viral factories (Figure 1E, H). Third, a VACV strain lacking both A49 and F14 (vv811 Δ A49 Δ F14) is less able to suppress cytokine-stimulated NF- κ B-dependent gene expression than vv811 Δ A49 (Figure 1I). Fourth, following TNF- α stimulation, I κ B α degradation, IKK-mediated phosphorylation of p65 at Ser⁵³⁶ and p65 accumulation in the nucleus remained unaffected in the presence of F14 (Figure 2A, B). And fifth, F14 blocked NF- κ B-dependent gene expression stimulated by p65 overexpression, indicating that it acts at or downstream of p65 (Figure 2C). Lastly, despite the presence of several other VACV encoded NF- κ B inhibitors, the biological importance of F14 was illustrated by its contribution to virulence (Figure 1F, G), a feature shared with many immunomodulatory proteins from VACV, including some inhibitors of NF- κ B [reviewed by [50, 51]].

Mechanistically, F14 inhibits NF- κ B via a C-terminal 23 aa motif, resembling p65 acidic activation domain, which disrupts the binding of p65 to its coactivator CBP (Figures 4 and 5). Consequently, F14 reduces acetylation of p65 Lys³¹⁰ and subsequent recruitment of BRD4 to the *CXCL10* promoter, but not to the *NFKBIA* promoter (Figure 7). These findings correlated with F14 suppressing *CXCL10* (and *CCL2*), but not *NFKBIA* (and *CXCL8*), mRNA expression (Figure 6A, B, D, E). The selective inhibition of a subset of NF- κ B-dependent genes by F14, despite the interference with molecular events deemed important for p65-mediated transactivation, underscores the complexity of the nuclear actions of NF- κ B. Initial understanding of NF- κ B-mediated gene activation was derived mostly using artificial reporter plasmids, but subsequent genome-wide, high-throughput studies uncovered diverse mechanisms of gene activation [14, 16, 24, 29, 30, 85, 86]. Because multiple promoters containing κ B sites are preloaded with CBP/p300, RNAP II and general transcription factors, the activation of transcription by NF- κ B relies on the recruitment of BRD4 [85, 86].

Recruitment of BRD4 to the promoters and enhancers occurs via bromodomain-mediated docking onto acetylated lysine residues on either histones or non-histone proteins and promotes RNAP II processivity [reviewed by [77]]. BRD4 is recruited to NF- κ B-bound promoters via the recognition of p65 acetylated at Lys³¹⁰ [40]. This explains the observation that BRD4 is less enriched on the *CXCL10* promoter following TNF- α stimulation in the presence of F14, which is associated with the reduced acetylation of p65 by CBP (Figure 7A, B, D). Nonetheless, BRD4 enrichment on *NFKBIA* promoter remained unaffected in the presence of F14 (Figure 7C), suggesting the existence of alternative mechanisms of BRD4

1 recruitment to the promoter of NF- κ B-responsive genes. It is possible that acetylated
2 histones mediate BRD4 recruitment to some NF- κ B-bound promoters in the absence of
3 acetylated p65. For instance, histone 4 acetylated on Lys⁵, Lys⁸ and Lys¹² (H4K5/K8/K12ac)
4 is responsible for BRD4 recruitment to NF- κ B-responsive genes upon lipopolysaccharide
5 stimulation [85]. Alternatively, the genes whose expression is insensitive to F14 might be
6 activated independently of the p65 TA₁ domain, as it is the case of some NF- κ B-responsive
7 genes in mouse fibroblasts stimulated with TNF- α , including *Nfkb1a*. For those genes, p65
8 occupancy on the promoter elements suffices for gene activation, via recruitment of
9 secondary transcription factors [24].

10 In the nucleus, p65 engages with multiple binding partners via its transactivation domains,
11 including the direct interactions between TA₁ and TA₂ and the KIX and transcriptional
12 adaptor zinc finger (TAZ) 1 domains of CBP, respectively. These interactions are mediated
13 by hydrophobic contacts of the ϕ xx ϕ motifs and complemented by electrostatic contacts by
14 the acidic residues surrounding the hydrophobic motifs [74, 86]. Sequence analysis
15 suggested that F14 mimics the p65 TA₁ domain (Figure 3A). Indeed, fusion of the TAD-like
16 domain of F14 to a p65 mutant lacking the TA₁ domain restored its transactivation activity to
17 wildtype levels (Figure 3E). This explains a rather spurious observation from a yeast two-
18 hybrid screen of VACV protein-protein interactions, in which F14 could not be tested
19 because it was found to be a strong activator when fused to the Gal4 DNA-binding domain
20 [87]. Site-directed mutagenesis of F14 revealed that the dipeptide Asp^{62/63}, but not Leu⁶⁵ or
21 Leu⁶⁸ of the ϕ xx ϕ motif, is required for inhibition of NF- κ B (Figure 4A), for interaction with
22 CBP (Figure 4B) and for the efficient disruption of p65 binding to CBP (Figure 5D). This
23 contrasts with the molecular determinants of p65 TA₁ binding to the KIX domain of CBP,
24 which is dependent on the hydrophobic residues of the ϕ xx ϕ motif, particularly Phe⁵⁴² [74].
25 In the future, solving the structure of F14 TAD-like domain in complex with the KIX domain
26 will provide insight into this discrepancy and shed light on how VACV evolved to inhibit NF-
27 κ B via molecular mimicry of p65 TAD. Nonetheless, the conservation of the Asp^{62/63} site in all
28 orthopoxvirus species (Figure 3A) implies an important function.

29 The diminished acetylation of p65 Lys³¹⁰ is a direct consequence of the disruption of CBP
30 and p65 interaction by F14. Other poxvirus proteins are reported to inhibit p65 acetylation.
31 For instance, ectopic expression of VACV protein K1 inhibited CBP-dependent p65
32 acetylation and NF- κ B-dependent gene expression [88], whilst during infection, K1 inhibited
33 NF- κ B activation upstream of I κ B α degradation [89]. Regardless whether K1 inhibits NF- κ B
34 upstream or downstream of p65, the vv811 Δ A49 strain used to predict the existence of
35 additional VACV inhibitors of NF- κ B lacks K1 [56]. The other poxviral protein that inhibits
36 CBP-mediated acetylation of p65, and thereby NF- κ B activation, is encoded by gene 002 of
37 orf virus, a parapoxvirus that causes mucocutaneous infections in goats and sheep [90].
38 However, protein 002 differs from F14 in that it interacts with p65 to prevent phosphorylation
39 at p65 Ser²⁷⁶ and the subsequent acetylation at Lys³¹⁰ by p300 [90, 91].

40 F14 causes diminished p65 Lys³¹⁰ acetylation and consequential reduced recruitment of
41 BRD4 to *CXCL10* promoter. The interaction between BRD4 and p65 can also reduce
42 ubiquitylation and proteasomal degradation of nuclear p65 [92]. Thus, in addition to reducing
43 BRD4 recruitment to the promoters of a subset of NF- κ B-responsive genes, F14 could also
44 destabilise nuclear p65 to terminate the pro-inflammatory signal. This represents an
45 interesting avenue for future investigation. From the viral perspective, the selective inhibition
46 of only a subset of NF- κ B-responsive genes by F14 might represent an adaptation to more
47 efficiently counteract the host immune response. If an NF- κ B-activating signal reached the
48 nucleus of an infected cell, maintaining expression of some NF- κ B-dependent genes,
49 particularly *NFKB1A*, might promote inhibition of pathway activation by I κ B α . Newly

1 synthesised I κ B α not only tethers cytoplasmic NF- κ B, but can also remove NF- κ B from the
2 DNA and cause its export from the nucleus [17, 18, 93].

3 Our recent proteomic analysis of VACV infection revealed that both CBP and p300 are
4 degraded in proteasome-dependent manner during infection [69]. The proteasomal
5 degradation of CBP/p300 might be an additional immune evasion strategy of VACV, given its
6 role in the activation of gene expression downstream of NF- κ B and other immune signalling
7 pathways, like IRF3 [94] and IFN-stimulated JAK/STAT [95, 96]. Because of the widespread
8 distribution of CBP/p300-binding sites in enhancer and promoter elements across the
9 genome, one can predict that the VACV-induced downregulation of these histone
10 acetyltransferases will have far-reaching consequences on the host gene expression (Wang
11 et al., 2009).

12 This study adds VACV protein F14 to the list of viral binding partners of CBP and its
13 paralogue p300, which includes adenovirus E1A protein [97], human immunodeficiency virus
14 (HIV) 1 Tat protein [98], human T-cell lymphotropic virus (HTLV) 1 Tax protein [99], high-risk
15 HPV E6 protein [100], and polyomavirus T antigen [101]. Despite the fact that some of these
16 proteins also inhibit NF- κ B activation [79, 100, 102], F14 is unique among them in mimicking
17 p65 TA₁ to bind to CBP and prevent its interaction with p65. After searching for additional
18 viral proteins that might mimic p65 TAD, we focused on HPV E7 and HSV-1 VP16. The latter
19 protein has a prototypical acidic TAD (Figure 8A), the former bears a motif resembling the
20 ϕ xx ϕ motif (Figure 8B), and both proteins inhibit NF- κ B activation [78-82]. Data presented
21 here confirm that VP16 and, to a lesser extent, E7 each inhibit NF- κ B-dependent gene
22 expression (Figure 8A, B). However, neither co-precipitated CBP under conditions in which
23 F14 did (Figure 8C), suggesting VP16 and E7 inhibit NF- κ B activation by a mechanism
24 distinct from F14. The interaction between VP16 and CBP is contentious [21, 78] and data
25 presented here suggest that these two proteins do not associate with each other under the
26 conditions tested.

27 Overall, our search for additional inhibitors of NF- κ B activation encoded by VACV unveiled a
28 unique viral strategy to inhibit this transcription factor that is required for the host antiviral
29 and inflammatory responses. The detailed mechanism of how the VACV protein F14
30 suppresses NF- κ B activation is described. By mimicking the TA₁ domain of p65, F14
31 disrupts the interaction between p65 and its coactivator CBP, thus inhibiting the downstream
32 molecular events that trigger the activation of a subset of inflammatory genes in response to
33 cytokine stimulation. Moreover, the contribution of F14 to virulence highlighted its
34 physiological relevance. The molecular mimicry of F14 might be only rivalled by that of the
35 avian reticuloendotheliosis virus, a retrovirus whose *v-Rel* gene was acquired from an avian
36 host and modified to inhibit p65-dependent gene activation [reviewed by [103]].

37

1 MATERIALS AND METHODS

2 *Sequence analysis*

3 Candidate open reading frames (ORFs) encoding the unknown VACV inhibitor of NF- κ B
4 were first selected based on VACV genomes available on the NCBI database (accession
5 numbers: NC_006998.1 for the Western Reserve strain, and M35027.1 for the Copenhagen
6 strain). The prediction of molecular mass and isoelectric point (pI), and of nuclear
7 localisation signal (NLS) sequences, of the candidate VACV gene products was done with
8 ExPASy Compute pI/MW tool (https://web.expasy.org/compute_pi/) and SeqNLS
9 (<http://mleg.cse.sc.edu/seqNLS/>, [104], respectively. Domain searches were performed
10 using InterPro (<http://www.ebi.ac.uk/interpro/search/sequence/>), UniProt
11 (<https://www.uniprot.org/uniprot/>), HHpred (<https://toolkit.tuebingen.mpg.de/tools/hhpred/>),
12 PCOILS (<https://toolkit.tuebingen.mpg.de/tools/pcoils/>), and Phobius
13 (<https://www.ebi.ac.uk/Tools/pfa/phobius/>) [105]. Gene family searches were done within the
14 Pfam database (<https://pfam.xfam.org/>) and conservation within the poxvirus family, with
15 Viral Orthologous Clusters (<https://4virology.net/virology-ca-tools/vocs/>) [72] and protein
16 BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) searches. Phyre2
17 (<http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index>) [73] was used for the prediction
18 of F14 protein structure. Multiple sequence alignments were performed using Clustal Omega
19 (<https://www.ebi.ac.uk/Tools/msa/clustalo/>) and ESPript 3.0
20 (<http://esprict.ibcp.fr/ESPript/ESPript/>) [106] was used for the visualisation of protein
21 sequence alignments.

23 *Expression vectors*

24 The VACV F14L ORF (strain Western Reserve) was codon-optimised for expression in
25 human cells and synthesised by GeneArt (Thermo Fisher Scientific), with an optimal 5'
26 Kozak sequence and fused to an N-terminal FLAG epitope. For ease of subsequent
27 subcloning, 5' BamHI and 3' XbaI restriction sites were included as well as a NotI site
28 between the epitope tag and the ORF. For mammalian expression, N-terminal FLAG-tagged
29 F14 was subcloned between the BamHI and XbaI restriction sites of a pcDNA4/TO vector
30 (Invitrogen). Alternatively, codon-optimised F14 was PCR-amplified to include a 3' HA tag or
31 a 3' FLAG or no epitope tag, and 5' BamHI and 3' XbaI sites to clone into pcDNA4/TO
32 plasmid. In addition, codon-optimised F14 sequence was PCR-amplified to include 5' BamHI
33 and 3' NotI sites to facilitate cloning into a pcDNA4/TO-based vector containing a TAP tag
34 sequence after the NotI site; the TAP tag consisted of two copies of the Strep-tag II epitope
35 and one copy of the FLAG epitope [107]. Mutant F14 expression vectors were constructed
36 with QuikChange II XL Site-Directed Mutagenesis kit (Agilent), using primers containing the
37 desired mutations and C-terminal TAP-tagged codon-optimised F14 cloned into pcDNA4/TO
38 as template. Expression vectors for VACV proteins C6 and B14 have been described [64,
39 108].

40 The ORF encoding HPV16 E7 protein was amplified from a template kindly provided by Dr.
41 Christian Kranjec and Dr. John Doorbar (Dept. Pathology, Cambridge, UK) and cloned into
42 5' BamHI and 3' NotI sites of a pcDNA4/TO-based vectors fused to a C-terminal TAP tag or
43 HA epitope. Vectors expressing mutant E7 proteins were generated by site-directed
44 mutagenesis as described above. The ORF encoding HSV-1 VP16 and Δ TAD mutant
45 (lacking aa 413-490) were amplified from a pEGFP-C2-based VP16 expression plasmid
46 kindly provided by Dr. Colin Crump (Dept. Pathology, Cambridge, UK) and cloned into 5'
47 BamHI and 3' NotI sites of a pcDNA4/TO-based vector fused to a C-terminal HA epitope.

Plasmids encoding TAP- and HA-tagged p65 were described elsewhere [83] and plasmids expressing FLAG-tagged mouse CBP, and HA-tagged mouse CBP were kind gift from Prof. Gerd A. Blobel (University of Pennsylvania, Philadelphia, USA) and Prof. Tony Kouzarides (Dept. Pathology and The Gurdon Institute, Cambridge, UK). Firefly luciferase reporter plasmids for NF- κ B, ISRE and AP-1, as well as the constitutively active TK-*Renilla* luciferase reporter plasmid were kind gifts from Prof. Andrew Bowie (Trinity College, Dublin, Republic of Ireland).

The oligonucleotide primers used for cloning and site-directed mutagenesis are listed in Table S1. Nucleotide sequences of the inserts in all the plasmids were verified by Sanger DNA sequencing.

Cell lines

All cell lines were grown in medium supplemented with 10% foetal bovine serum (FBS, Pan Biotech), 100 units/mL of penicillin and 100 μ g/mL of streptomycin (Gibco), at 37°C in a humid atmosphere containing 5% CO₂. Human embryo kidney (HEK) 293T epithelial cells, and monkey kidney BS-C-1 and CV-1 epithelial cells were grown in Dulbecco's modified Eagle's medium (DMEM, Gibco). Rabbit kidney RK13 epithelial cells were grown in minimum essential medium (MEM, Gibco) and human cervix HeLa epithelial cells, in MEM supplemented with non-essential amino acids (Gibco). T-REx-293 cells (Invitrogen) were grown in DMEM supplemented with blasticidin (10 μ g/mL, InvivoGen), whilst the growth medium of T-REx-293-derived cell lines stably transfected with pcDNA4/TO-based plasmids was further supplemented with zeocin (100 μ g/mL, Gibco).

The absence of mycoplasma contamination in the cell cultures was tested routinely with MycoAlert detection kit (Lonza), following the manufacturer's recommendations.

Construction of recombinant viruses

A VACV Western Reserve (WR) strain lacking F14 (Δ F14) was constructed by introduction of a 137-bp internal deletion in the *F14L* ORF by transient dominant selection [109]. A DNA fragment including the first 3 bp of *F14L* ORF and 297 bp upstream, intervening NotI and HindIII sites, and the last 82 bp of the ORF and 218 bp downstream were generated by overlapping PCR and inserted into the PstI and BamHI sites of pUC13-Ecogpt-EGFP plasmid, containing the *Escherichia coli* guanylylphosphoribosyl transferase (Ecogpt) gene fused in-frame with the enhanced green fluorescent protein (EGFP) gene under the control of the VACV 7.5K promoter [68]. The resulting plasmid contained an internal deletion of the *F14L* ORF (nucleotide positions 42049-42185 from VACV WR reference genome, accession number NC_006998.1). The remaining sequence of *F14L* was out-of-frame and contained multiple stop codons, precluding the expression of a truncated version of F14. The derived plasmid was transfected into CV-1 cells that had been infected with VACV-WR at 0.1 p.f.u./cell for 1 h. After 48 h, progeny viruses that incorporated the plasmid by recombination and expressed the Ecogpt-EGFP were selected and plaque-purified three times on monolayers of BS-C-1 cells in the presence of mycophenolic acid (25 μ g/mL), supplemented with hypoxanthine (15 μ g/mL) and xanthine (250 μ g/mL). The intermediate recombinant virus was submitted to three additional rounds of plaque purification in the absence of the selecting drugs and GFP-negative plaques were selected. Under these conditions, progeny viruses can undergo a second recombination that result in loss of the Ecogpt-EGFP cassette concomitantly with either incorporation of the desired mutation (Δ F14) or reversal to wild

type genotype (vF14). Because vΔF14 and vF14 are sibling strains derived from the same intermediate virus, they are genetically identical except for the 137-bp deletion in the *F14L* locus. Viruses were analysed by PCR to identify recombinants by distinguishing wild type and ΔF14 alleles, and the presence or absence of the Ecogpt-EGFP cassette.

To restore F14 expression in vΔF14, the *F14L* locus was amplified by PCR, including about 250 bp upstream and downstream of the ORF, and inserted into the PstI and BamHI sites of pUC13-Ecogpt-EGFP plasmid. Additionally, *F14L* ORF fused to the sequence coding a C-terminal TAP tag was also amplified by overlapping PCR, including the same flanking sequences described above, and inserted into the PstI and BamHI sites of pUC13-Ecogpt-EGFP plasmid. By using the same transient dominant selection method, these plasmids were used to generate two revertant strains derived from vΔF14: (i) vF14-Rev, in which F14 expression from its natural locus was restored, and (ii) vF14-TAP, expressing F14 fused to a C-terminal TAP tag under the control of its natural promoter. The vC6-TAP virus was described elsewhere [108].

A VACV vv811 strain lacking both A49 and F14 (vv811ΔA49ΔF14) was also constructed by transient dominant selection. The resultant virus contained the same 137-bp internal deletion in the *F14L* ORF within the vv811ΔA49 strain generated previously [56]. The distinction between wild type and ΔF14 alleles in the obtained viruses, and the presence or absence of the Ecogpt-EGFP cassette, was determined by PCR analysis.

The oligonucleotide primers used to generate the recombinant VACV strains are listed in Table S1. To verify that all the final recombinant viruses harboured the correct sequences, PCR fragments spanning the *F14L* locus were sequenced.

Preparation of virus stocks

The stocks of virus strains derived from VACV WR were prepared in RK-13 cells. Cells grown to confluence in T-175 flasks were infected at 0.01 p.f.u./cell until complete cytopathic effect was visible. The cells were harvested by centrifugation, suspended in a small volume of DMEM supplemented with 2% FBS, and submitted to multiple cycles of freezing/thawing and sonication to lyse the cells and disrupt aggregates of virus particles and cellular debris. These crude virus stocks were used for experiments in cultured cells. Crude stocks of vv811 and derived strains were prepared in the same way, except for the BS-C-1 cells used for infection. For the *in vivo* work, virus stocks were prepared by ultracentrifugation of the cytoplasmic fraction of infected cell lysates through sucrose cushion and suspension of the virus samples in 10 mM Tris-HCl pH 9.0 [110]. The viral titres in the stocks were determined by plaque assay on BS-C-1 cells.

Virus growth and spread assays

To analyse virus growth properties in cell culture, single-step growth curve experiments were performed in HeLa cells. Cells were grown to about 90% confluence in T-25 flasks and then infected at 5 p.f.u./cell in growth medium supplemented with 2% FBS. Virus adsorption was at 37°C for 1 h. Then the inoculum was removed, and the cells were replenished with growth medium supplemented with 2% FBS. At 1, 8, and 24 h p.i., infected-cell supernatants and monolayers were collected for determination of extracellular and cell-associated infectious virus titres by plaque assay on BS-C-1 cells. Supernatants were clarified by centrifugation to remove cellular debris and detached cells, whereas cell monolayers were

scraped and disrupted by three cycles of freezing/thawing followed by sonication, to release intracellular virus particles.

The virus spread in cell culture was assessed by plaque formation. Confluent monolayers of BS-C-1 cells in 6-well plates were infected with 50 p.f.u./well and overlaid with MEM supplemented with 2% FBS and 1.5% carboxymethylcellulose. After 48 h, infected cell monolayers were stained with 0.5% crystal violet solution in 20% methanol and imaged.

Construction of inducible F14-expressing T-REx-293 cell line

T-REx-293 cells (Invitrogen), which constitutively expresses the Tet repressor (TetR) under the control of the human cytomegalovirus (HCMV) immediate early promoter, were transfected with pcDNA4/TO-coF14-TAP plasmid, which encodes human codon-optimised F14 fused to a C-terminal TAP tag under the control of the HCMV immediate early promoter and two tetracycline operator 2 (TetO₂) sites. Transfected cells were selected in the presence of blasticidin (10 µg/mL) and zeocin (100 µg/mL) and clonal cell lines were obtained by limiting dilution. Expression of protein F14 within these clones was analysed by immunoblotting and flow cytometry with anti-FLAG antibodies.

Reporter gene assays

HEK 293T cells in 96-well plates were transfected in quadruplicate with firefly luciferase reporter plasmid (NF-κB, ISRE, or AP-1), TK-*Renilla* luciferase reporter plasmid (as an internal control) and the desired expression vectors or empty vector (EV) using *TransIT*-LT1 transfection reagent (Mirus Bio), according to the manufacturer's instruction. On the following day, cells were stimulated with TNF-α (10 ng/ml, PeproTech) or IL-1β (20 ng/ml, PeproTech) for 8 h (for NF-κB activation), IFN-α2 (1000 U/ml, PeproTech) for 8 h (for JAK/STAT/ISRE activation), or phorbol 12-myristate 13-acetate (10 ng/ml) for 24 h (for MAPK/AP-1 activation). Alternatively, NF-κB was activated by co-transfection of p65-overexpressing plasmid and cells were harvested 24 h after transfection.

To measure NF-κB activation during infection, A549 cells transduced with a lentiviral vector expressing the firefly luciferase under the control of an NF-κB promoter (A549-NF-κB-Luc) [56] were grown in 96-well plates and infected with VACV vv811 and derived strains at 5 p.f.u./cell. After 6 h, cells were stimulated with TNF-α (10 ng/ml, PeproTech) or IL-1β (20 ng/ml, PeproTech) for an additional 6 h. In parallel, A549-NF-κB-Luc cells grown in 6-well plates were infected with the equivalent amount of virus for 12 h and cell lysates were analysed by immunoblotting.

Cells were lysed using passive lysis buffer (Promega) and firefly and *Renilla* luciferase luminescence was measured using a FLUOstar luminometer (BMG). Promoter activity was obtained by calculation of firefly/*Renilla* luciferase ratios and the promoter activity under pathway stimulation was normalised to the activity of the respective non-stimulated control of each protein under test. In parallel, aliquots of the replicas of each condition tested were combined, mixed with 5 × SDS-polyacrylamide gel loading buffer, and immunoblotted to confirm the expression of the proteins tested.

Virus infection in cell culture

HeLa or HEK 293T cells in 6-well plates (for protein expression analyses) or 10-cm dishes (for immunoprecipitation experiments) were infected at 5 p.f.u./cell. Viral inocula were prepared in growth medium supplemented with 2% FBS. Viral adsorption was done at 37°C for 1 h, after which the medium supplemented with 2% FBS was topped up to the appropriate vessel volume and cells were incubated at 37°C.

In vivo experiments

All animal experiments were conducted according to the Animals (Scientific Procedures) Act 1986 under the license PPL 70/8524. Mice were purchased from Envigo and housed in specific pathogen-free conditions in the Cambridge University Biomedical Services facility.

For the intradermal (i.d.) model of infection, female C57BL/6 mice (6-8-week old) were inoculated with 10⁴ p.f.u. in both ear pinnae and the diameter of the lesion was measured daily using a micrometer [111]. For the intranasal (i.n.) model, female BALB/c mice (6-8-week old) were inoculated 5 × 10³ p.f.u. divided equally into each nostril and were weighed daily [112]. In both cases, viral inocula were prepared in phosphate-buffered saline (PBS) supplemented with 0.01% bovine serum albumin (BSA, Sigma Aldrich) and the infectious titres in the administered inocula were confirmed by plaque assay.

For quantification of virus replication after the i.d. infection, infected mice were culled 3, 7, and 10 d p.i. and ear tissues were collected, homogenised and passed through a 70-µm nylon mesh using DMEM containing 10% FBS. Samples were frozen and thawed three times, sonicated thoroughly to liberate cell-associated virus particles, and the infectious titres present were determined by plaque assay on BS-C-1 cells.

Immunoblotting

For analysis of protein expression, cells were washed with ice-cold PBS and lysed on ice with cell lysis buffer [50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100 and 0.05% (v/v) Nonidet P-40 (NP-40)], supplemented with protease (cOmplete Mini, Roche) and phosphatase inhibitors (PhosSTOP, Roche), for 20 min. Lysed cells were scraped and lysates were clarified to remove insoluble material by centrifugation at 17,000 × g for 15 min at 4°C. Protein concentration in the cell lysate was determined using a bicinchoninic acid protein assay kit (Pierce). After mixing with 5 × SDS-gel loading buffer and boiling at 100°C for 5 min, equivalent amounts of protein samples were loaded onto SDS-polyacrylamide gels or NuPAGE 4 to 12% Bis-Tris precast gels (Invitrogen), separated by electrophoresis and transferred onto nitrocellulose membranes (GE Healthcare). Membranes were blocked at room temperature with either 5% (w/v) non-fat milk or 3% (w/v) BSA (Sigma Aldrich) in Tris-buffered saline (TBS) containing 0.1% (v/v) Tween-20. To detect the expression of the protein under test, the membranes were incubated with specific primary antibodies diluted in blocking buffer at 4°C overnight. After washing with TBS containing 0.1% (v/v) Tween-20, membranes were probed with fluorophore-conjugated secondary antibodies (LI-COR Biosciences) diluted in 5% (w/v) non-fat milk at room temperature for 1 h. The antibodies used for immunoblotting are listed in Table S2. After washing, membranes were imaged using the Odyssey CLx imaging system (LI-COR Biosciences), according to the manufacturer's instructions. For quantitative analysis of protein levels, the band intensities on the immunoblots were quantified using the Image Studio software (LI-COR Biosciences).

1

2 *Co-immunoprecipitation and pulldown assays*

3 HEK 293T or HeLa cells in 10-cm dishes were infected at 5 p.f.u./cell for 8 h or transfected
4 overnight with the specified epitope-tagged plasmids using polyethylenimine (PEI,
5 Polysciences, 2 µl of 1 mg/ml stock per µg of plasmid DNA). For the competition assays,
6 cells were starved of FBS for 3 h and stimulated with TNF-α (40 ng/ml, PeproTech) in FBS-
7 free DMEM for 15 min before harvesting. Cells were washed twice with ice-cold PSB,
8 scraped in immunoprecipitation (IP) buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5%
9 (v/v) NP-40), 0.1 mM EDTA), supplemented with protease (cOmplete Mini, Roche) and
10 phosphatase (PhosSTOP, Roche) inhibitors, on ice, transferred to 1.5-ml microcentrifuge
11 tubes and rotated for 30 min at 4°C. Cell lysates were centrifuged at 17,000 × g for 15 min
12 at 4°C and the soluble fractions were incubated with 20 µl of one of the following affinity
13 resins equilibrated in IP buffer: (i) anti-FLAG M2 (Sigma Aldrich) for IP of FLAG- or TAP-
14 tagged proteins; (ii) anti-HA (Sigma Aldrich) for IP of HA-tagged proteins; or (iii) Strep-Tactin
15 Superflow resin (IBA) for pulldown of TAP-tagged protein via Strep-tag II epitope. After 2 h of
16 rotation at 4°C, the protein-bound resins were washed three times with ice-cold IP buffer.
17 The bound proteins were eluted by incubation with 2× SDS-gel loading buffer and boiled at
18 100°C for 5 min before analysis by SDS-polyacrylamide gel electrophoresis and
19 immunoblotting, along with 10% input samples collected after clarification of cell lysates.

20

21 *Reverse transcription and quantitative PCR*

22 To analyse mRNA expression of NF-κB-responsive genes, T-REx-293-F14 and T-REx-293-
23 C6 cells in 12-well plates were induced overnight with 100 ng/ml doxycycline (Melford, UK)
24 to induce the expression of the VACV proteins. The next day, cells were starved for 3 h by
25 removal of serum from the medium and then stimulated in duplicate with TNF-α (40 ng/ml,
26 PeproTech) in FBS-free DMEM for 0, 1 or 6 h. RNA was extracted using RNeasy Mini Kit
27 (Qiagen) and complementary DNA (cDNA) was synthesised using SuperScript III reverse
28 transcriptase (Invitrogen) and oligo-dT primers (Thermo Scientific), according to the
29 instructions of the respective manufacturers. The mRNA levels of CCL2, CXCL8, CXCL10,
30 GAPDH and NFKBIA were quantified by quantitative PCR using gene-specific primer sets,
31 fast SYBR green master mix (Applied Biosystems) and the ViiA 7 real-time PCR system (Life
32 Technologies). The oligonucleotide primers used for the qPCR analysis of gene expression
33 are listed in Table S1. Fold-induction of the NF-κB-responsive genes was calculated by the
34 $2^{-\Delta\Delta C_t}$ method using non-stimulated T-REx-293-C6 as the reference sample and *GAPDH* as
35 the housekeeping control gene.

36

37 *Enzyme-linked immunosorbent assay (ELISA)*

38 The secretion of CXCL8 and CXCL10 was measured by ELISA. T-REx-293-EV, T-REx-293-
39 B14, T-REx-293-C6 and T-REx-293-F14 cells in 12-well plates were incubated overnight in
40 the presence or absence of 100 ng/ml doxycycline (Melford, UK) to induce VACV protein
41 expression. The next day, cells were stimulated in triplicate with TNF-α (40 ng/ml,
42 PeproTech) in DMEM supplemented with 2% FBS for 16 h. The supernatants were assayed
43 for human CXCL8 and CXCL10 using the respective DuoSet ELISA kits (R&D Biosystems),
44 according to the manufacturer's instructions.

45

Immunofluorescence

For immunofluorescence microscopy, T-REx-293-EV, T-REx-293-B14, T-REx-293-C6 and T-REx-293-F14 cells on poly-D-lysine-treated glass coverslips placed inside 6-well plates. Following induction of protein expression with 100 ng/ml doxycycline (Melford, UK) overnight, cells were starved of serum for 3 h and then stimulated with 40 ng/ml TNF- α (PeproTech) in FBS-free DMEM for 15 min. At the moment of harvesting, the cells were washed twice with ice-cold PBS and fixed in 4% (v/v) paraformaldehyde. After quenching of free formaldehyde with 150 mM ammonium chloride, the fixed cells were permeabilised with 0.1% (v/v) Triton X-100 in PBS and blocked with 10% (v/v) FBS in PBS. Antibody staining was carried out with mouse anti-p65 (Santa Cruz) and rabbit anti-FLAG (Sigma Aldrich) antibodies for 1 h, followed by incubation with the appropriate AlexaFluor fluorophore-conjugated secondary antibodies (Invitrogen Molecular Probes) and mounting onto glass slides with Mowiol 4-88 (Calbiochem) containing 0.5 μ g/ml DAPI (4',6-diamidino-2-phenylindole, Sigma Aldrich). The antibodies used for immunofluorescence are listed in Table S2. Images were acquired on an LSM 700 confocal microscope (Zeiss) using ZEN system software (Zeiss). Quantification of nuclear localisation of p65 was done manually on the ZEN lite (blue edition, Zeiss).

18

Chromatin immunoprecipitation and quantitative PCR (ChIP-qPCR)

T-REx-F14 cells in 15-cm dishes were incubated overnight in the absence or in the presence of 100 ng/ml doxycycline (Melford, UK) to induce F14 expression. The next day, cells were starved of FBS for 3 h and stimulated with TNF- α (40 ng/ml, PeproTech) in FBS-free DMEM for 0, 1 or 5 h. Cells were crosslinked with 1% (v/v) formaldehyde added directly to the growth medium. After 10 min at room temperature, crosslinking was stopped by the addition of 0.125 M glycine. Cells were then lysed in 0.2% NP-40, 10 mM Tris-HCl pH 8.0, 10 mM NaCl, supplemented with protease (cOmplete Mini, Roche), phosphatase (PhosSTOP, Roche) and histone deacetylase (10 mM sodium butyrate, Sigma Aldrich) inhibitors, and nuclei were recovered by centrifugation at 600 $\times$ g for 5 min at 4°C. To prepare the chromatin, nuclei were lysed in 1% (w/v) SDS, 50 mM Tris-HCl pH 8.0, 10 mM EDTA, plus protease/phosphatase/histone acetylase inhibitors, and lysates were sonicated in a Bioruptor Pico (Diagenode) to achieve DNA fragments of about 500 bp. After sonication, samples were centrifuged at 3,500 $\times$ g for 10 min at 4°C and supernatants were diluted four-fold in IP dilution buffer [20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% (v/v) Triton X-100, 0.01% (w/v) SDS] supplemented with protease/phosphatase/histone acetylase inhibitors.

Protein G-conjugated agarose beads (GE Healthcare) equilibrated in IP dilution buffer were used to preclear the chromatin for 1 h at 4°C with rotation. Before the immunoprecipitation, 20% of the precleared chromatin was kept as input control. Immunoprecipitation was performed with 8 μ g of anti-BRD4 antibody (Cell Signalling Technology, #13440) or anti-GFP (Abcam, #ab290), used as negative IgG control, overnight 4°C with rotation. Protein-DNA immunocomplexes were retrieved by incubation with 60 μ l of equilibrated protein G-conjugated agarose beads (GE Healthcare), for 2 h at 4°C, followed by centrifugation at 5,000 $\times$ g for 2 min at 4°C. Immunocomplex-bound beads were then washed: (i) twice with IP wash I [20 mM Tris-HCl pH 8.0, 50 mM NaCl, 2 mM EDTA, 1% (v/v) Triton X-100, 0.1% (w/v) SDS]; (ii) once with IP wash buffer II [10 mM Tris-HCl pH 8.0, 250 mM LiCl, 1 mM EDTA, 1% (v/v) NP-40, 1% (w/v) sodium deoxycholate]; and (iii) twice with TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA). Antibody-bound chromatin was eluted with 1% SDS, 100 mM

1 sodium bicarbonate for 15 min at room temperature. Formaldehyde crosslinks were reversed
 2 by incubation overnight at 67°C in presence of 1 µg of RNase A and 300 mM NaCl, followed
 3 by proteinase K digestion for 2 h at 45°C. Co-immunoprecipitated DNA fragments were
 4 purified using the QIAquick PCR purification kit (Qiagen) and analysed by quantitative PCR
 5 targeting the promoter elements of *NFKBIA* and *CXCL10* containing κB sites. The
 6 oligonucleotide primers used for the qPCR analysis of ChIP are listed in Table S1. For
 7 display of the ChIP-qPCR data, the signals obtained from the ChIP with each antibody were
 8 divided by the signals obtained from the corresponding input sample.

9

10 *Statistical analysis*

11 Experimental data are presented as means + s.d. or means ± s.e.m. for *in vivo* results,
 12 unless otherwise stated in figure legends. Statistical significance was calculated by two-
 13 tailed unpaired Student's *t*-test. GraphPad Prism software (version 8.4.2) was used for
 14 statistical analysis.

15

1 ACKNOWLEDGEMENTS

2 The authors thank Rachel Seear, Stephanie Macilwee, and Jemma Milburn for technical
3 support. We also thank John Doorbar (Dept. Pathology, University of Cambridge, UK), Colin
4 Crump (Dept. Pathology, University of Cambridge, UK), Tony Kouzarides (Dept. Pathology
5 and The Gurdon Institute, University of Cambridge, UK), and Gerd Blobel (University of
6 Pennsylvania, Philadelphia, USA) for providing us with reagents. We are also grateful to
7 Tony Kouzarides for helpful advice and to Callum Talbot-Cooper for critical reading of the
8 manuscript.

9

10 FUNDING

11 This work was supported by grant 090315 from the Wellcome Trust (to G.L.S.). J.D.A. was a
12 postdoctoral fellow of the Science without Borders programme from CNPq-Brazil (grant
13 235246/2014-0).

14

15 AUTHOR CONTRIBUTION

16 Conceptualisation: JDA, AAT, GLS

17 Methodology: JDA, HR, AAT, EVS, CAM, AJB

18 Software: N/A

19 Validation: JDA, HR, AAT, EVS

20 Formal Analysis: JDA, HR

21 Investigation: JDA, HR, AAT, EVS

22 Resources: AAT, CAM, AJB, GLS

23 Data Curation: JDA

24 Writing – Original Draft Preparation: JDA

25 Writing – Review and Editing: JDA, HR, AAT, CAM, AJB, GLS

26 Visualisation: JDA

27 Supervision: JDA, GLS

28 Project Administration: JDA, GLS

29 Funding: JDA, GLS

30

1 REFERENCES

- 2 1. Elde, N.C., et al., *Protein kinase R reveals an evolutionary model for defeating viral mimicry*.
3 Nature, 2009. **457**(7228): p. 485-9.
- 4 2. Hancks, D.C., et al., *Overlapping Patterns of Rapid Evolution in the Nucleic Acid Sensors cGAS*
5 *and OAS1 Suggest a Common Mechanism of Pathogen Antagonism and Escape*. PLoS Genet,
6 2015. **11**(5): p. e1005203.
- 7 3. Alves, J.M., et al., *Parallel adaptation of rabbit populations to myxoma virus*. Science, 2019.
8 **363**(6433): p. 1319-1326.
- 9 4. Medzhitov, R., *Recognition of microorganisms and activation of the immune response*.
10 Nature, 2007. **449**(7164): p. 819-26.
- 11 5. Iwasaki, A., *A virological view of innate immune recognition*. Annu Rev Microbiol, 2012. **66**:
12 p. 177-96.
- 13 6. Griffith, J.W., C.L. Sokol, and A.D. Luster, *Chemokines and chemokine receptors: positioning*
14 *cells for host defense and immunity*. Annu Rev Immunol, 2014. **32**: p. 659-702.
- 15 7. Netea, M.G., et al., *A guiding map for inflammation*. Nat Immunol, 2017. **18**(8): p. 826-831.
- 16 8. Altan-Bonnet, G. and R. Mukherjee, *Cytokine-mediated communication: a quantitative*
17 *appraisal of immune complexity*. Nat Rev Immunol, 2019. **19**(4): p. 205-217.
- 18 9. Bonilla, F.A. and H.C. Oettgen, *Adaptive immunity*. J Allergy Clin Immunol, 2010. **125**(2 Suppl
19 2): p. S33-40.
- 20 10. Hayden, M.S. and S. Ghosh, *Signaling to NF-kappaB*. Genes Dev, 2004. **18**(18): p. 2195-224.
- 21 11. Vallabhapurapu, S. and M. Karin, *Regulation and function of NF-kappaB transcription factors*
22 *in the immune system*. Annu Rev Immunol, 2009. **27**: p. 693-733.
- 23 12. Brubaker, S.W., et al., *Innate immune pattern recognition: a cell biological perspective*. Annu
24 Rev Immunol, 2015. **33**: p. 257-90.
- 25 13. Chen, L.F. and W.C. Greene, *Shaping the nuclear action of NF-kappaB*. Nat Rev Mol Cell Biol,
26 2004. **5**(5): p. 392-401.
- 27 14. Kaikkonen, M.U., et al., *Remodeling of the enhancer landscape during macrophage*
28 *activation is coupled to enhancer transcription*. Mol Cell, 2013. **51**(3): p. 310-25.
- 29 15. Tian, B., D.E. Nowak, and A.R. Brasier, *A TNF-induced gene expression program under*
30 *oscillatory NF-kappaB control*. BMC Genomics, 2005. **6**: p. 137.
- 31 16. Zhao, M., et al., *Transcriptional outcomes and kinetic patterning of gene expression in*
32 *response to NF-kappaB activation*. PLoS Biol, 2018. **16**(9): p. e2006347.
- 33 17. Huang, T.T., et al., *A nuclear export signal in the N-terminal regulatory domain of*
34 *IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha*
35 *complexes*. Proc Natl Acad Sci U S A, 2000. **97**(3): p. 1014-9.
- 36 18. Johnson, C., D. Van Antwerp, and T.J. Hope, *An N-terminal nuclear export signal is required*
37 *for the nucleocytoplasmic shuttling of IkappaBalpha*. EMBO J, 1999. **18**(23): p. 6682-93.
- 38 19. Barboric, M., et al., *NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA*
39 *polymerase II*. Mol Cell, 2001. **8**(2): p. 327-37.
- 40 20. Gerritsen, M.E., et al., *CREB-binding protein/p300 are transcriptional coactivators of p65*.
41 Proc Natl Acad Sci U S A, 1997. **94**(7): p. 2927-32.
- 42 21. Naar, A.M., et al., *Composite co-activator ARC mediates chromatin-directed transcriptional*
43 *activation*. Nature, 1999. **398**(6730): p. 828-32.
- 44 22. Schmitz, M.L., et al., *Interaction of the COOH-terminal transactivation domain of p65 NF-*
45 *kappa B with TATA-binding protein, transcription factor IIB, and coactivators*. J Biol Chem,
46 1995. **270**(13): p. 7219-26.
- 47 23. Sheppard, K.A., et al., *Transcriptional activation by NF-kappaB requires multiple coactivators*.
48 Mol Cell Biol, 1999. **19**(9): p. 6367-78.
- 49 24. van Essen, D., et al., *Two modes of transcriptional activation at native promoters by NF-*
50 *kappaB p65*. PLoS Biol, 2009. **7**(3): p. e73.

- 1 25. Saccani, S., S. Pantano, and G. Natoli, *Modulation of NF-kappaB activity by exchange of*
2 *dimers*. Mol Cell, 2003. **11**(6): p. 1563-74.
- 3 26. Thanos, D. and T. Maniatis, *Virus induction of human IFN beta gene expression requires the*
4 *assembly of an enhanceosome*. Cell, 1995. **83**(7): p. 1091-100.
- 5 27. Ashall, L., et al., *Pulsatile stimulation determines timing and specificity of NF-kappaB-*
6 *dependent transcription*. Science, 2009. **324**(5924): p. 242-6.
- 7 28. Hoffmann, A., et al., *The IkappaB-NF-kappaB signaling module: temporal control and*
8 *selective gene activation*. Science, 2002. **298**(5596): p. 1241-5.
- 9 29. Jin, F., et al., *PU.1 and C/EBP(alpha) synergistically program distinct response to NF-kappaB*
10 *activation through establishing monocyte specific enhancers*. Proc Natl Acad Sci U S A, 2011.
11 **108**(13): p. 5290-5.
- 12 30. Ramirez-Carrozzi, V.R., et al., *A unifying model for the selective regulation of inducible*
13 *transcription by CpG islands and nucleosome remodeling*. Cell, 2009. **138**(1): p. 114-28.
- 14 31. Ainbinder, E., et al., *Mechanism of rapid transcriptional induction of tumor necrosis factor*
15 *alpha-responsive genes by NF-kappaB*. Mol Cell Biol, 2002. **22**(18): p. 6354-62.
- 16 32. Saccani, S., S. Pantano, and G. Natoli, *Two waves of nuclear factor kappaB recruitment to*
17 *target promoters*. J Exp Med, 2001. **193**(12): p. 1351-9.
- 18 33. Huang, B., et al., *Posttranslational modifications of NF-kappaB: another layer of regulation*
19 *for NF-kappaB signaling pathway*. Cell Signal, 2010. **22**(9): p. 1282-90.
- 20 34. Perkins, N.D., *Post-translational modifications regulating the activity and function of the*
21 *nuclear factor kappa B pathway*. Oncogene, 2006. **25**(51): p. 6717-30.
- 22 35. Sakurai, H., et al., *IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the*
23 *transactivation domain*. J Biol Chem, 1999. **274**(43): p. 30353-6.
- 24 36. Zhong, H., R.E. Voll, and S. Ghosh, *Phosphorylation of NF-kappa B p65 by PKA stimulates*
25 *transcriptional activity by promoting a novel bivalent interaction with the coactivator*
26 *CBP/p300*. Mol Cell, 1998. **1**(5): p. 661-71.
- 27 37. Chen, L.F., et al., *NF-kappaB RelA phosphorylation regulates RelA acetylation*. Mol Cell Biol,
28 2005. **25**(18): p. 7966-75.
- 29 38. Wang, Z., et al., *Genome-wide mapping of HATs and HDACs reveals distinct functions in*
30 *active and inactive genes*. Cell, 2009. **138**(5): p. 1019-31.
- 31 39. Yang, F., et al., *IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine*
32 *536 induced by lipopolysaccharide*. J Immunol, 2003. **170**(11): p. 5630-5.
- 33 40. Huang, B., et al., *Brd4 coactivates transcriptional activation of NF-kappaB via specific binding*
34 *to acetylated RelA*. Mol Cell Biol, 2009. **29**(5): p. 1375-87.
- 35 41. Amir-Zilberstein, L., et al., *Differential regulation of NF-kappaB by elongation factors is*
36 *determined by core promoter type*. Mol Cell Biol, 2007. **27**(14): p. 5246-59.
- 37 42. Nowak, D.E., et al., *RelA Ser276 phosphorylation is required for activation of a subset of NF-*
38 *kappaB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes*. Mol
39 Cell Biol, 2008. **28**(11): p. 3623-38.
- 40 43. Smale, S.T., *Hierarchies of NF-kappaB target-gene regulation*. Nat Immunol, 2011. **12**(8): p.
41 689-94.
- 42 44. Peng, C., et al., *Myxoma virus M156 is a specific inhibitor of rabbit PKR but contains a loss-of-*
43 *function mutation in Australian virus isolates*. Proc Natl Acad Sci U S A, 2016. **113**(14): p.
44 3855-60.
- 45 45. Elde, N.C. and H.S. Malik, *The evolutionary conundrum of pathogen mimicry*. Nat Rev
46 Microbiol, 2009. **7**(11): p. 787-97.
- 47 46. Daugherty, M.D. and H.S. Malik, *Rules of engagement: molecular insights from host-virus*
48 *arms races*. Annu Rev Genet, 2012. **46**: p. 677-700.
- 49 47. McFadden, G., *Poxvirus tropism*. Nat Rev Microbiol, 2005. **3**(3): p. 201-13.
- 50 48. Johnston, J.B. and G. McFadden, *Poxvirus immunomodulatory strategies: current*
51 *perspectives*. J Virol, 2003. **77**(11): p. 6093-100.

- 1 49. Seet, B.T., et al., *Poxviruses and immune evasion*. Annu Rev Immunol, 2003. **21**: p. 377-423.
- 2 50. Smith, G.L., et al., *Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity*. J Gen Virol, 2013. **94**(Pt 11): p. 2367-2392.
- 3 51. Albarnaz, J.D., A.A. Torres, and G.L. Smith, *Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory*. Viruses, 2018. **10**(3).
- 4 52. Bahar, M.W., et al., *How vaccinia virus has evolved to subvert the host immune response*. J Struct Biol, 2011. **175**(2): p. 127-34.
- 5 53. Mansur, D.S., et al., *Poxvirus targeting of E3 ligase beta-TrCP by molecular mimicry: a mechanism to inhibit NF-kappaB activation and promote immune evasion and virulence*. PLoS Pathog, 2013. **9**(2): p. e1003183.
- 6 54. Neidel, S., et al., *Vaccinia virus protein A49 is an unexpected member of the B-cell Lymphoma (Bcl)-2 protein family*. J Biol Chem, 2015. **290**(10): p. 5991-6002.
- 7 55. Neidel, S., et al., *NF-kappaB activation is a turn on for vaccinia virus phosphoprotein A49 to turn off NF-kappaB activation*. Proc Natl Acad Sci U S A, 2019. **116**(12): p. 5699-5704.
- 8 56. Sumner, R.P., et al., *Vaccinia virus inhibits NF-kappaB-dependent gene expression downstream of p65 translocation*. J Virol, 2014. **88**(6): p. 3092-102.
- 9 57. Perkus, M.E., et al., *Deletion of 55 open reading frames from the termini of vaccinia virus*. Virology, 1991. **180**(1): p. 406-10.
- 10 58. Assarsson, E., et al., *Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes*. Proc Natl Acad Sci U S A, 2008. **105**(6): p. 2140-5.
- 11 59. Yang, Z., et al., *Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing*. Proc Natl Acad Sci U S A, 2010. **107**(25): p. 11513-8.
- 12 60. Wenthe, S.R. and M.P. Rout, *The nuclear pore complex and nuclear transport*. Cold Spring Harb Perspect Biol, 2010. **2**(10): p. a000562.
- 13 61. Gubser, C., et al., *Poxvirus genomes: a phylogenetic analysis*. J Gen Virol, 2004. **85**(Pt 1): p. 105-117.
- 14 62. Chen, R.A., et al., *Inhibition of IkappaB kinase by vaccinia virus virulence factor B14*. PLoS Pathog, 2008. **4**(2): p. e22.
- 15 63. Stuart, J.H., et al., *Vaccinia Virus Protein C6 Inhibits Type I IFN Signalling in the Nucleus and Binds to the Transactivation Domain of STAT2*. PLoS Pathog, 2016. **12**(12): p. e1005955.
- 16 64. Torres, A.A., et al., *Multiple Bcl-2 family immunomodulators from vaccinia virus regulate MAPK/AP-1 activation*. J Gen Virol, 2016. **97**(9): p. 2346-2351.
- 17 65. Yang, Z., et al., *Deciphering poxvirus gene expression by RNA sequencing and ribosome profiling*. J Virol, 2015. **89**(13): p. 6874-86.
- 18 66. Yang, Z., et al., *Genome-wide analysis of the 5' and 3' ends of vaccinia virus early mRNAs delineates regulatory sequences of annotated and anomalous transcripts*. J Virol, 2011. **85**(12): p. 5897-909.
- 19 67. Yuen, L. and B. Moss, *Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes*. Proc Natl Acad Sci U S A, 1987. **84**(18): p. 6417-21.
- 20 68. Unterholzner, L., et al., *Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7*. PLoS Pathog, 2011. **7**(9): p. e1002247.
- 21 69. Soday, L., et al., *Quantitative Temporal Proteomic Analysis of Vaccinia Virus Infection Reveals Regulation of Histone Deacetylases by an Interferon Antagonist*. Cell Rep, 2019. **27**(6): p. 1920-1933 e7.
- 22 70. Parrish, S. and B. Moss, *Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression*. J Virol, 2006. **80**(2): p. 553-61.
- 23 71. Parrish, S. and B. Moss, *Characterization of a second vaccinia virus mRNA-decapping enzyme conserved in poxviruses*. J Virol, 2007. **81**(23): p. 12973-8.

- 1 72. Ehlers, A., et al., *Poxvirus Orthologous Clusters (POCs)*. Bioinformatics, 2002. **18**(11): p. 1544-5.
- 2
- 3 73. Kelley, L.A., et al., *The Phyre2 web portal for protein modeling, prediction and analysis*. Nat Protoc, 2015. **10**(6): p. 845-58.
- 4
- 5 74. Lecoq, L., et al., *Structural characterization of interactions between transactivation domain 1 of the p65 subunit of NF-kappaB and transcription regulatory factors*. Nucleic Acids Res, 2017. **45**(9): p. 5564-5576.
- 6
- 7
- 8 75. Schmitz, M.L., et al., *Structural and functional analysis of the NF-kappa B p65 C terminus. An acidic and modular transactivation domain with the potential to adopt an alpha-helical conformation*. J Biol Chem, 1994. **269**(41): p. 25613-20.
- 9
- 10
- 11 76. Schmitz, M.L. and P.A. Baeuerle, *The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B*. EMBO J, 1991. **10**(12): p. 3805-17.
- 12
- 13 77. Shi, J. and C.R. Vakoc, *The mechanisms behind the therapeutic activity of BET bromodomain inhibition*. Mol Cell, 2014. **54**(5): p. 728-36.
- 14
- 15 78. Xing, J., et al., *Herpes simplex virus 1-encoded tegument protein VP16 abrogates the production of beta interferon (IFN) by inhibiting NF-kappaB activation and blocking IFN regulatory factor 3 to recruit its coactivator CBP*. J Virol, 2013. **87**(17): p. 9788-801.
- 16
- 17
- 18 79. Huang, S.M. and D.J. McCance, *Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF*. J Virol, 2002. **76**(17): p. 8710-21.
- 19
- 20
- 21 80. Richards, K.H., et al., *The human papillomavirus (HPV) E7 protein antagonises an Imiquimod-induced inflammatory pathway in primary human keratinocytes*. Sci Rep, 2015. **5**: p. 12922.
- 22
- 23 81. Spitkovsky, D., et al., *The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the Ikappa B kinase complex*. J Biol Chem, 2002. **277**(28): p. 25576-82.
- 24
- 25
- 26 82. Vandermark, E.R., et al., *Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization*. Virology, 2012. **425**(1): p. 53-60.
- 27
- 28
- 29 83. Pallett, M.A., et al., *Vaccinia Virus BBK E3 Ligase Adaptor A55 Targets Importin-Dependent NF-kappaB Activation and Inhibits CD8(+) T-Cell Memory*. J Virol, 2019. **93**(10).
- 30
- 31 84. Eaglesham, J.B., et al., *Viral and metazoan poxins are cGAMP-specific nucleases that restrict cGAS-STING signalling*. Nature, 2019. **566**(7743): p. 259-263.
- 32
- 33 85. Hargreaves, D.C., T. Horng, and R. Medzhitov, *Control of inducible gene expression by signal-dependent transcriptional elongation*. Cell, 2009. **138**(1): p. 129-45.
- 34
- 35 86. Mukherjee, S.P., et al., *Analysis of the RelA:CBP/p300 interaction reveals its involvement in NF-kappaB-driven transcription*. PLoS Biol, 2013. **11**(9): p. e1001647.
- 36
- 37 87. McCraith, S., et al., *Genome-wide analysis of vaccinia virus protein-protein interactions*. Proc Natl Acad Sci U S A, 2000. **97**(9): p. 4879-84.
- 38
- 39 88. Bravo Cruz, A.G. and J.L. Shisler, *Vaccinia virus K1 ankyrin repeat protein inhibits NF-kappaB activation by preventing RelA acetylation*. J Gen Virol, 2016. **97**(10): p. 2691-2702.
- 40
- 41 89. Shisler, J.L. and X.L. Jin, *The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation*. J Virol, 2004. **78**(7): p. 3553-60.
- 42
- 43 90. Diel, D.G., et al., *A nuclear inhibitor of NF-kappaB encoded by a poxvirus*. J Virol, 2011. **85**(1): p. 264-75.
- 44
- 45 91. Ning, Z., et al., *The N terminus of orf virus-encoded protein 002 inhibits acetylation of NF-kappaB p65 by preventing Ser(276) phosphorylation*. PLoS One, 2013. **8**(3): p. e58854.
- 46
- 47 92. Zou, Z., et al., *Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA*. Oncogene, 2014. **33**(18): p. 2395-404.
- 48
- 49 93. Sun, S.C., et al., *NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway*. Science, 1993. **259**(5103): p. 1912-5.
- 50

- 1 94. Lin, R., et al., *Virus-dependent phosphorylation of the IRF-3 transcription factor regulates*
2 *nuclear translocation, transactivation potential, and proteasome-mediated degradation*. Mol
3 Cell Biol, 1998. **18**(5): p. 2986-96.
- 4 95. Bhattacharya, S., et al., *Cooperation of Stat2 and p300/CBP in signalling induced by*
5 *interferon-alpha*. Nature, 1996. **383**(6598): p. 344-7.
- 6 96. Zhang, J.J., et al., *Two contact regions between Stat1 and CBP/p300 in interferon gamma*
7 *signaling*. Proc Natl Acad Sci U S A, 1996. **93**(26): p. 15092-6.
- 8 97. O'Connor, M.J., et al., *Characterization of an E1A-CBP interaction defines a novel*
9 *transcriptional adapter motif (TRAM) in CBP/p300*. J Virol, 1999. **73**(5): p. 3574-81.
- 10 98. Marzio, G., et al., *HIV-1 tat transactivator recruits p300 and CREB-binding protein histone*
11 *acetyltransferases to the viral promoter*. Proc Natl Acad Sci U S A, 1998. **95**(23): p. 13519-24.
- 12 99. Nicot, C. and R. Harrod, *Distinct p300-responsive mechanisms promote caspase-dependent*
13 *apoptosis by human T-cell lymphotropic virus type 1 Tax protein*. Mol Cell Biol, 2000. **20**(22):
14 p. 8580-9.
- 15 100. Patel, D., et al., *The E6 protein of human papillomavirus type 16 binds to and inhibits co-*
16 *activation by CBP and p300*. EMBO J, 1999. **18**(18): p. 5061-72.
- 17 101. Eckner, R., et al., *Association of p300 and CBP with simian virus 40 large T antigen*. Mol Cell
18 Biol, 1996. **16**(7): p. 3454-64.
- 19 102. Cook, J.L., et al., *Role of the E1A Rb-binding domain in repression of the NF-kappa B-*
20 *dependent defense against tumor necrosis factor-alpha*. Proc Natl Acad Sci U S A, 2002.
21 **99**(15): p. 9966-71.
- 22 103. Gilmore, T.D., *Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein*
23 *v-Rel*. Oncogene, 1999. **18**(49): p. 6925-37.
- 24 104. Lin, J.R., et al., *Minimalist ensemble algorithms for genome-wide protein localization*
25 *prediction*. BMC Bioinformatics, 2012. **13**: p. 157.
- 26 105. Kall, L., A. Krogh, and E.L. Sonnhammer, *A combined transmembrane topology and signal*
27 *peptide prediction method*. J Mol Biol, 2004. **338**(5): p. 1027-36.
- 28 106. Robert, X. and P. Gouet, *Deciphering key features in protein structures with the new*
29 *ENDscript server*. Nucleic Acids Res, 2014. **42**(Web Server issue): p. W320-4.
- 30 107. Gloeckner, C.J., et al., *A novel tandem affinity purification strategy for the efficient isolation*
31 *and characterisation of native protein complexes*. Proteomics, 2007. **7**(23): p. 4228-34.
- 32 108. Maluquer de Motes, C., et al., *Vaccinia virus virulence factor N1 can be ubiquitinated on*
33 *multiple lysine residues*. J Gen Virol, 2014. **95**(Pt 9): p. 2038-2049.
- 34 109. Falkner, F.G. and B. Moss, *Transient dominant selection of recombinant vaccinia viruses*. J
35 Virol, 1990. **64**(6): p. 3108-11.
- 36 110. Joklik, W.K., *The purification of four strains of poxvirus*. Virology, 1962. **18**: p. 9-18.
- 37 111. Tschärke, D.C. and G.L. Smith, *A model for vaccinia virus pathogenesis and immunity based*
38 *on intradermal injection of mouse ear pinnae*. J Gen Virol, 1999. **80** (Pt 10): p. 2751-2755.
- 39 112. Williamson, J.D., et al., *Biological characterization of recombinant vaccinia viruses in mice*
40 *infected by the respiratory route*. J Gen Virol, 1990. **71** (Pt 11): p. 2761-7.

41

42

1 FIGURE LEGENDS

2

3 **Figure 1: Vaccinia virus protein F14 inhibits NF-κB activation and contributes to**
4 **virulence.** (A-D) HEK 293T cells were transfected with reporter plasmids NF-κB-Fluc (firefly
5 luciferase) (A, B), ISRE-Fluc (C), or AP1-Fluc (D), TK-*Renilla*, and vectors expressing the
6 indicated VACV proteins fused to a FLAG or tandem affinity purification (TAP) epitope or
7 empty vector (EV). After 16 h, cells were stimulated with TNF-α, IL-1β or IFN-α (as indicated)
8 for additional 8 h (A-C) or 24 h (D), when luciferase activities were measured. Means + s.d.
9 ($n = 4$ per condition) are shown. (E) Aliquots from whole cell lysates prepared for dual
10 luciferase reporter gene assays were analysed by SDS-PAGE and immunoblotting with anti-
11 FLAG and anti-α-tubulin antibodies. (F) C57BL/6 mice were infected intradermally in both
12 ears with 10^4 p.f.u. of the indicated VACV strains and the lesions were measured daily with a
13 calliper. Means ± s.e.m. ($n = 10$ mice) are shown. The asterisk (*) indicates the days on
14 which the lesion size caused by vΔF14 was statistically different ($P < 0.05$) from both vF14
15 and vF14-Rev. (G) Virus titres in the ears of mice infected as in (F) at 3, 7 and 10 d p.i. were
16 determined by plaque assay. Means ± s.e.m. ($n = 5$ mice) are shown. (H) Immunoblot
17 showing F14 expression during infection. HeLa cells were infected with vF14-TAP at 5
18 p.f.u./cell for the indicated times and cytosine arabinoside (AraC, 40 μg/ml) was added
19 where indicated. Immunoblots with antibodies to FLAG (F14), VACV proteins C6 and D8,

1 and α -tubulin. (I) A549 cells transduced with reporter NF- κ B-Fluc were infected with VACV
2 vv811 strains at 5 p.f.u./cell. At 6 h p.i. cells were stimulated with TNF- α or IL-1 β for 8 h and
3 then luciferase activities were measured. Means + s.d. ($n = 4$ per condition) are shown. (J)
4 Immunoblots of protein extracts from A549-NF- κ B-Fluc cells infected as indicated with
5 antibodies against VACV protein A49, whole VACV virions, and α -tubulin. (E, H, J) The
6 positions of molecular mass markers in kDa are shown on the left of immunoblots. Statistical
7 significance was determined by the Student's t -test (**** $P < 0.0001$, *** $P < 0.001$, ** $P < 0.01$,
8 * $P < 0.05$). Data shown in (A-D, I), (F, G) and (E, H, J) are representative of four, two or
9 three separate experiments, respectively.

10

Figure 2: F14 inhibits NF-κB at or downstream of p65. (A) Immunoblot showing levels of IκBα, Ser⁵³⁶-phosphorylated p65, total p65, F14 (anti-FLAG) and α-tubulin in T-REx-293 cells inducibly expressing F14 (+ doxycycline) and stimulated with TNF-α as indicated. Data are representative of three independent experiments. (B) T-REx-293 cells inducibly expressing the empty vector (EV) or VACV proteins B14, C6 or F14 were induced with

1 doxycycline overnight and then stimulated with TNF- α for 15 min. Subcellular localisation of
2 NF- κ B p65 subunit was assessed by immunofluorescence. The percentages of cells
3 displaying nuclear p65 are shown, with n (number of cells counted from two independent
4 experiments) stated underneath each bar. (C) HEK 293T cells were transfected with reporter
5 plasmids NF- κ B-Fluc, TK-*Renilla*, and vectors expressing human p65-TAP, VACV proteins
6 B14-FLAG and F14-TAP or empty vector (EV). After 24 h, luciferase activities were
7 measured. Top panel: Means + s.d. ($n = 4$ per condition) are shown. Statistical significance
8 was determined by Student's t -test (**** $P < 0.0001$). Bottom panel: immunoblots of proteins
9 detected with antibody against the FLAG epitope, and α -tubulin. Protein molecular mass
10 markers in kDa are shown on the left of the blots.

11

Figure 3: F14 binds to CBP and has transactivation activity. (A) Amino acid alignment of F14 orthologues of representative orthopoxviruses: vaccinia virus (VACV) Western Reserve (WR), VACV Copenhagen (Cop), modified vaccinia Ankara (MVA), horsepox virus (HSPV), monkeypox virus (MPXV), cowpox virus (CPXV), variola virus (VARV), camelpox virus (CMLV), taterapox virus (TATV), ectromelia virus (ECMV), and racoonpox virus (RCNV). Red = aa identical in all sequences. Yellow = aa identical in 8/11 sequences. Alignment of the C-termini of F14 and p65 highlighting their sequence similarity including the φxxφφ motif, above a schematic of p65 and its functional domains. (B, C) Lysates from HEK 293T cells

1 expressing GFP-HA, F14-HA and CBP-FLAG were immunoprecipitated with anti-HA (**B**) or
2 anti-FLAG (**C**) and immunoblotted for FLAG- and HA-tagged proteins, and α -tubulin.
3 Immunoblots are representative of three independent experiments. (**D**) HEK 293T and HeLa
4 cells were infected with VACV strains vC6-TAP or vF14-TAP at 5 p.f.u./cell for 8 h. Cell
5 lysates were immunoprecipitated with anti-FLAG and immunoblotted for CBP, FLAG-tagged
6 C6 and F14, VACV protein D8, and α -tubulin. Immunoblots are representative of two
7 independent experiments. (**E**) HEK 293T cells were transfected with NF- κ B-Fluc, TK-*Renilla*,
8 and vectors expressing human p65-TAP, or p65-TAP mutants or empty vector (EV). Top
9 panel: After 24 h, luciferase activities were measured. Means + s.d. ($n = 4$ per condition) are
10 shown. Statistical significance was determined by the Student's t -test (**** $P < 0.0001$).
11 Bottom panel: immunoblots of p65 (anti-FLAG) and α -tubulin. Protein molecular mass
12 markers in kDa are shown on the left of the blots.

13

Figure 4: The dipeptide Asp^{62/63} of F14 is required for inhibition of NF-κB. (A) HEK 293T cells were transfected with NF-κB-Fluc, TK-*Renilla*, and increasing concentrations of vectors expressing VACV protein F14 or the indicated mutants, or empty vector (EV). After 16 h, cells were stimulated with TNF-α for 8 h, and then luciferase activities were measured. Top panel: Means + s.d. ($n = 4$ per condition) are shown. Bottom panel: Immunoblots. Aliquots of whole cell lysates prepared for dual luciferase reporter gene assays were blotted with antibodies against FLAG and α-tubulin. Data are representative of three independent

1 experiments. Statistical significance was determined by the Student's *t*-test (****P < 0.0001,
 2 ***P<0.001, **P < 0.01, *P < 0.05). (B) Lysates from HEK 293T cells expressing the
 3 indicated proteins were affinity purified with StrepTactin resin and immunoblotted for FLAG
 4 and α-tubulin. Immunoblots are representative of three independent experiments. DD/AA
 5 denotes D62/63A mutant and DD/KK, D62/63K mutant. Protein molecular mass markers in
 6 kDa are shown on the left of the blots.

7

Figure 5: F14 outcompetes NF- κ B for binding to CBP. (A, D) Lysates from HEK 293T cells expressing the indicated proteins and stimulated with TNF- α for 15 min were immunoprecipitated with anti-FLAG (A) or anti-HA (D) and immunoblotted for FLAG, HA and α -tubulin. Immunoblots are representative of three independent experiments. (B, C) Ratio of immunoprecipitate (IP) over input signal intensities from immunoblots as in (A). Means + s.d. ($n = 3$ independent experiments) are shown. Statistical significance was determined by the Student's t -test (* $P < 0.05$). Protein molecular mass markers in kDa are shown on the left of the blots.

Figure 6: F14 suppresses expression of a subset of NF-κB-responsive genes. (A, B, D, E) T-REx-293 cells were induced with doxycycline overnight to express VACV proteins C6 or F14, and then stimulated with TNF-α for 1 or 6 h. Total RNA was extracted, and mRNA for indicated NF-κB-responsive genes was analysed by RT-qPCR. Means ± s.d. ($n = 2$ per condition) are shown. **(C, F)** T-REx-293 cells inducibly expressing the empty vector (EV) or VACV proteins B14, C6 or F14 were induced with doxycycline overnight and then stimulated with TNF-α for 16 h. The concentration of CXCL8 and CXCL10 in the culture supernatants was measured by ELISA. Means ± s.d. ($n = 3$ per condition) of the percent of secretion in presence of doxycycline (+dox) in comparison to secretion in the absence of doxycycline (-dox, equals 100%) are shown. Statistical significance was determined by the Student's t -test (**** $P < 0.0001$, *** $P < 0.001$, ** $P < 0.01$, * $P < 0.05$). **(G, H)** Protein extracts from T-REx-293 cell lines were immunoblotted with antibodies against the FLAG or α -tubulin. Protein molecular masses in kDa are shown on the left of the blots.

Figure 7: F14 antagonises p65 acetylation and BRD4 recruitment to *CXCL10* promoter.

(A) Immunoblot analysis of p65 Lys³¹⁰ acetylation. T-REx-293 cells stably transfected with empty vector (EV) or a plasmid inducibly expressing F14 were induced with doxycycline overnight. Cells were then transfected with plasmids for expression of p65-TAP and FLAG-CBP overnight and lysates were immunoblotted with anti-FLAG and anti- α -tubulin. Blots are representative of two independent experiments carried out with three biological replicates each. (B) Ratio of acetylated (Ac) p65 over total ectopic p65 signal intensities from immunoblots in (A). Means + s.d. ($n = 3$ per condition) are shown. (C, D) T-REx-293 cells stably expressing inducible F14 were induced with doxycycline overnight before stimulation with TNF- α for 1 or 5 h. Chromatin immunoprecipitation (ChIP) was carried out with anti-BRD4 antibody or control IgG, and immunoprecipitated DNA was analysed by qPCR for the promoters of *NFKBIA* (C) and *CXCL10* (D) genes. Means + s.d. ($n = 3$ per condition) are shown. Statistical significance was determined by the Student's t -test (** $P < 0.01$, * $P < 0.05$). (E) Immunoblots of protein extracts from T-REx-293 cells harvested in parallel to ChIP to detect the expression of F14-FLAG and α -tubulin. Protein molecular mass markers in kDa are shown on the left of the blots.

Figure 8: F14 is a unique viral inhibitor of NF-κB. (A) Top: Amino acid sequence of the TAD of HSV-1 VP16 with the acidic activation domain similar to p65 highlighted in red. Middle: HEK 293T cells were transfected with NF-κB-Fluc, TK-*Renilla* and increasing concentrations of vectors expressing VP16 or a mutant lacking the TAD domain, or empty vector (EV). After 16 h, cells were stimulated with TNF-α for 8 h and then luciferase activities were measured. Means + s.d. ($n = 4$ per condition) are shown. Bottom: Aliquots from whole cell lysates prepared for dual luciferase reporter gene assays were immunoblotted with antibodies against HA and GAPDH. (B) Top: Amino acid residues 61-98 from HPV16 protein E7 encompassing a $\phi\chi\phi\phi$ motif containing and preceded by negatively charged residues. Highlighted are two residues mutated to disrupt this motif. Middle: Wildtype 16E7 and its two mutants (D75K and L83R) were tested in the NF-κB luciferase reporter gene assay as described in (A). Bottom: Immunoblots with antibodies against FLAG and α -tubulin. Statistical significance was determined by the Student's *t*-test (**** $P < 0.0001$, *** $P < 0.001$, ** $P < 0.01$). (C) Lysates from HEK 293T cells expressing VACV F14, HSV-1 VP16, HPV E7 and VACV C6 (all HA-tagged) were immunoprecipitated with anti-HA and immunoblotted for

- 1 FLAG, HA and α -tubulin. Immunoblots are representative of two independent experiments.
- 2 Protein molecular masses in kDa are shown on the left of the blots.
- 3

1 SUPPLEMENTARY MATERIAL

2

3

4 **Figure S1, related to Figure 1: Screen of VACV strain WR ORFs for NF- κ B inhibitory**
5 **activity.** HEK 293T cells were transfected with NF- κ B-Fluc, TK-*Renilla*, and vectors
6 expressing human codon-optimised and FLAG-tagged versions of the indicated VACV
7 proteins or empty vector (EV). After 16 h, cells were stimulated with TNF- α or mock
8 stimulated (NS) for 8 h, and then luciferase activities were measured. Means + s.d. ($n = 4$
9 per condition) are shown.

10

1

2 **Figure S2, related to Figure 1: Virulence of VACV mutant lacking F14 in the intranasal**
3 **mouse model of infection.** BALB/c mice were infected intranasally with 5×10^3 p.f.u. of the
4 indicated VACV strains and their body mass was measured daily. Body mass is expressed
5 as the percentage $\pm$ s.e.m. of the mean of the same group of mice on day 0 ($n = 10$ mice).

6

Figure S3, related to Figure 1: Replication and spread of VACV mutant lacking F14 in cell culture. (A, B) HeLa cells were infected with the indicated VACV strains at 5 p.f.u./cell. At 1, 12 and 24 h p.i., infectious virus titres associated with the cells (A) and in the supernatants (B) was determined by plaque assay. Means $\pm$ s.d. (n = 4 per condition) are shown. (C) Plaque formation by the indicated VACV strains on BS-C-1 cells.

Figure S4, related to Figure 6: F14 suppresses expression CXCL10, but not CXCL8, after stimulation with TNF- α . This shows data normalised for presentation in **Figure 6C, F**. T-REx-293 cells stably transfected with empty vector (EV) or plasmids inducibly expressing VACV proteins B14, C6 or F14 (all TAP-tagged) were induced with doxycycline (+dox) or mock-induced (-dox) overnight and then stimulated with TNF- α for 16 h. The concentration of CXCL8 and CXCL10 in the supernatants from these cells was measured by ELISA. Means + s.d. ($n = 3$ per condition) are shown. Statistical significance was determined by the Student's t -test (**** $P < 0.0001$, * $P < 0.05$).

Table S1: Oligonucleotide primers used in this study. Primers are listed 5' to 3'. Restriction sites used are highlighted in red and indicated in parentheses following oligonucleotide sequence. If present, sequences coding the tag epitopes are highlighted in bold, whilst the Kozak sequence are shown in italics. Plasmids marked with an asterisk (*) were constructed by site-directed mutagenesis, with the mutated codons underlined.

Table S2: Antibodies used in this study.